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Design and Synthesis of Imidazole and Triazole Pyrazoles
as Mycobacterium Tuberculosis CYP121A1 Inhibitors
Safaa M. Kishk,[a, b] Kirsty J. McLean,[c] Sakshi Sood,[d] Darren Smith,[a] Jack W.D. Evans,[a]
Mohamed A. Helal,[b, e] Mohamed S. Gomaa,[b, f] Ismail Salama,[b] Samia M. Mostafa,[b]
Luiz Pedro S. de Carvalho,[d] Colin W. Levy,[c] Andrew W. Munro,[c] and Claire Simons*[a]
The emergence of untreatable drug-resistant strains of Myco-
bacterium tuberculosis is a major public health problem world-
wide, and the identification of new efficient treatments is
urgently needed. Mycobacterium tuberculosis cytochrome P450
CYP121A1 is a promising drug target for the treatment of
tuberculosis owing to its essential role in mycobacterial growth.
Using a rational approach, which includes molecular modelling
studies, three series of azole pyrazole derivatives were designed
through two synthetic pathways. The synthesized compounds
were biologically evaluated for their inhibitory activity towards
M. tuberculosis and their protein binding affinity (KD). Series 3
biarylpyrazole imidazole derivatives were the most effective
with the isobutyl (10f) and tert-butyl (10g) compounds
displaying optimal activity (MIC 1.562 μg/mL, KD 0.22 μM (10f)
and 4.81 μM (10g)). The spectroscopic data showed that all the
synthesised compounds produced a type II red shift of the
heme Soret band indicating either direct binding to heme iron
or (where less extensive Soret shifts are observed) putative
indirect binding via an interstitial water molecule. Evaluation of
biological and physicochemical properties identified the follow-
ing as requirements for activity: LogP >4, H-bond acceptors/H-
bond donors 4/0, number of rotatable bonds 5–6, molecular
volume >340 Å3, topological polar surface area <40 Å2.
1. Introduction
Tuberculosis (TB) is the ninth leading cause of death worldwide
and the leading cause from a single infectious agent, ranking
above HIV/AIDS.[1] In 2016, 6.3 million new cases of TB were
reported; of these there were an estimated 1.3 million deaths
among HIV-negative people and an estimated 374,000 deaths
among HIV-positive people.[1] Drug-resistant TB is a continuing
challenge, with an estimated 4.1% of new cases and 19% of
previously treated cases presenting with multidrug resistant
(MDR)/rifampicin resistant (RR) TB in 2016.[1] China, India and
the Russian Federation have the largest number of MDR/RR-TB
cases accounting for 47% of the global total.[1]
Drugs currently used to treat TB target cell wall synthesis
(e.g. isoniazid, ethambutol, cycloserine), protein synthesis (e.g.
capreomycin, kanamycin), RNA synthesis (e.g. rifampicin), DNA
gyrase (e. g. fluoroquinolones) and ATP synthase (e. g. bedaqui-
line and delamanid) in Mycobacterium tuberculosis (Mtb), the
causative agent of TB.[2] The first line TB drug regimen includes
a combination of isoniazid, ethambutol, rifampicin and pyrazi-
namide over a 6–9 month period and, whilst effective, this
therapy is associated with drug intolerance and toxicity.[3]
Treatment of MDR-TB and extensively drug resistant (XDR) TB is
more complex and also associated with increased side
effects.[2,4] The emergence of MDR-TB, XDR-TB and totally drug
resistant (TDR) Mtb strains has led to intensified research to
identify new anti-TB drugs over the past decade.
Mtb encodes twenty cytochrome P450 enzymes (CYPs or
P450s), three of these (CYP121A1, CYP125 A1 and CYP128 A1)
were shown to be essential for mycobacterial growth or survival
in the host.[5] CYP121A1 is of considerable interest from both a
biochemical and drug design perspective. CYP121A1 catalyses a
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unique C  C bond formation between carbon atoms in the
ortho-positions of two tyrosine groups in the cyclodipeptide
dicyclotyrosine (cYY, Figure 1), the natural substrate, to form
the metabolite mycocyclosin.[6] The role of mycocylosin in Mtb
remains unclear, although cyclodipeptides have important bio-
logical effects, such as inhibition of production of bacterial
virulence factors and biofilm formation.[7,8] Drug design for
CYP121A1 inhibitors has followed several approaches: (1) a
fragment-based approach has been very effective in developing
compounds with low nM enzyme binding affinity, however this
has not translated to antimycobacterial activity;[9,10] (2) a recent
biophysical screening of a library of described P450 inhibitors
has led to a promising lead compound with both good binding
affinity and antimycobacterial activity;[11] (3) our own approach
has focused on developing a series of different compound
scaffolds as mimics of cYY, resulting in both good binding
affinity and promising antimycobacterial activity.[12,13] Our pre-
vious research identified derivatives of (1,3-diphenyl)-4-((1,3-
imidazol-1-yl)methyl)-1H-pyrazole and 1-((1,3-diphenyl-1H-pyra-
zol-4-yl)methyl)-1H-[1,2,4]triazole as inhibitors of CYP121A1 (e.g.
1, 2 and 3, Figure 1),[13] representing lead compounds for further
development. Diphenyl pyrazole derivatives were found to
interact with the active site of CYP121A1 in a manner similar to
fluconazole and the natural substrate cYY (Figure 1), interacting
indirectly with the heme via an interstitial water molecule
(Figure 2).
Introduction of a N atom in one of the phenyl rings, i. e. a
pyridine ring, can potentially result in additional binding
interactions, which may improve binding affinity. Likewise,
extension of the chain between the pyrazole and the heme
prosthetic group may allow the molecule to interact directly
with the heme: this is the basis for Series 1 (Figure 3). The
requirement for two phenyl rings was also explored in Series 2
by preparation of a small series of imidazole/triazole derivatives,
with one of the phenyl rings replaced with a methyl group
(Figure 3). Finally, our previous research showed a direct
correlation between lipophilicity and MIC.[13] Therefore in Series
3 one of the phenyl rings is further substituted with a range of
alkyl substituted phenyl and biaryl groups to determine
structure-activity relationships (Figure 3).
2. Results and Discussion
2.1. Chemistry
Series 1 pyridylpyrazole imidazole compounds (10 and 11) were
obtained via a five-step synthetic route (Scheme 1) beginning
with the preparation of the imines (6)[14] on reaction of the
appropriate 3- or 4-acetylpyridine reagent (4) with phenyl-
hydrazine (5) under acidic conditions.[15,16] The yields obtained
for the imines (6) were 98 and 97% respectively for the 4-
pyridyl (6a) and 3-pyridyl (6b) imines. The aldehydes (7) were
prepared as previously described[14] by a Vilsmeier-Haack
reaction of the imines (6).
Reduction of the aldehydes (7) with NaBH4 resulted in high
yields of the corresponding alcohols (8). Thionyl chloride was
the chlorinating reagent used to convert the alcohols to the
Figure 1. Lead compounds (1–3), the natural substrate cYY and CYP121A1
inhibitor fluconazole.
Figure 2. (A) 3D and (B) 2D images of the binding interactions of lead
compound 1 in the CYP121A1 active site. Binding with the heme is through
an interstitial water molecule with Ser237, Gln385, Arg386 and Thr77 as key
binding amino acids.
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chlorides (9), different equivalents of thionyl chloride were used
to optimize the reaction conditions (1, 4 and 10 equivalents),
and the maximum yield was obtained when 10 equivalents of
the reagent were used. Reaction of the chlorides (9) with either
the potassium salt of imidazole or triazole, prepared in situ by
treatment of imidazole or triazole with potassium carbonate in
acetonitrile at 45 °C for 1 h,[12,13] and overnight reflux at 70 °C
gave the required final imidazole (10a and 10b) and triazole
(11a and 11b) pyridyl-pyrazole derivatives (Scheme 1) in yields
of 67, 54, 48 and 55% respectively.
To prepare the extended compounds, the aldehydes (7)
were oxidized with potassium permanganate to give the
carboxylic acids (12).[14] The carboxylic acids were then coupled
with either 1-(3-aminopropyl)imidazole or 4-(aminomethyl)
pyridine, after activation of the carboxylic acid with carbon-
yldiimidazole, to give the N-(1H-imidazolyl)propyl)-1-phenyl-3-
(pyridyl)-1H-pyrazole-4-carboxamides (13a and 13b) and 1-
phenyl-3-(pyridyl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxa-
mides (14a and 14b) (Scheme 1).
In series 2, one of the phenyl rings was replaced with a
methyl group to determine whether the second phenyl ring
was significant for enzyme binding and inhibitory activity.
For the remaining phenyl ring the 4-methoxy phenyl group
was chosen to more closely mimic the phenol ring of cYY
(Figure 1). The 3/5-((1H-imidazol-1-yl)methyl)-1-(4-methoxy-
phenyl)-5/3-methyl-1H-pyrazoles (23 and 25) and 1-((1-(4-
methoxyphenyl)-5/3-methyl-1H-pyrazol-3/5-yl)methyl)-1H-1,2,4-
triazoles (24 and 26) were prepared in four steps (Scheme 2).
Formation of the pyrazole ethyl esters (17 and 18) was achieved
by the reaction of ethyl-2,4-dioxovalerate (15) with 4-methox-
yphenyl hydrazine (16) by a Knorr pyrazole synthesis
mechanism[17] as previously described.[18] The two regioisomers,
ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylate
(17) and ethyl 1-(4-methoxyphenyl)-3-methyl-1H-pyrazole-5-
carboxylate (18) were obtained in a ratio of 1.3 : 1 and separated
by column chromatography. The ethyl esters (17 and 18) were
reduced to the alcohols 19 and 20 and then converted to the
chlorides using thionyl chloride (21 and 22) followed by
reaction with the potassium salt of imidazole or triazole, as
previously described, to give the required final imidazole
pyrazole derivatives (23 and 25) and triazole pyrazole deriva-
tives (24 and 26) (Scheme 2).
The Series 3 biarylpyrazole imidazole (10c-j) compounds
were obtained via the five-step synthetic route described in
Scheme 1 and were prepared to explore the effect of different
aryl and biaryl groups on binding and their ‘fit’ within the active
site, and also to evaluate the correlation between MIC and
lipophilicity previously observed. Of note, although the yields
obtained for the imines (6c–j) varied between 84–99%, they
were generally found to be highly sensitive to light and
moisture, especially those with low melting points, so were
used immediately in the next step of the reaction scheme. Also,
in the chlorination step of the indole derivative 8 j a C-2
chlorination of the indole ring occurred in addition to the
conversion of the alcohol to chloride.
Figure 3. Modifications of the lead compounds, generating Series 1, 2 and 3
Scheme 1. Reagents and Conditions: (i) AcOH, EtOH, 80 °C, 1 h (ii) POCl3, DMF,
60 °C, 4 h (iii) NaBH4, EtOH, r.t. 1 h (iv) SOCl2, CH2Cl2, r.t. overnight (v)
imidazole, K2CO3, CH3CN, 45 °C, 1 h then 70 °C, overnight (vi) triazole, K2CO3,
CH3CN, 45 °C, 1 h then 70 °C, overnight (vii) KMnO4, acetone/H2O, r.t. 1.5 h
(viii) (a) CDI, DMF, r.t. 2 h (b) 1-(3-aminopropyl)imidazole, 70 °C, 48 h (ix) (a)
CDI, DMF, r.t. 2 h (b) 4-(aminomethyl)pyridine, 70 °C, 48 h. [a, Ar=4-pyridyl;
b, Ar=3-pyridyl]
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2.2. CYP121A1 Ligand Binding Affinity
The CYP121A1 binding affinity (KD) of the various compounds
was determined by UV-vis optical titration. For CYP121A1, the
typical low-spin ligand free spectrum shows five characteristic
peaks; a protein peak from the aromatic amino acid residues at
280 nm, a Soret peak at 416.5 nm, the β band at 538 nm, the α
band at 565 nm, and small charge transfer band at ~650 nm
owing to a residual amount of high-spin heme iron. A heme
iron low-spin (LS) to high-spin (HS) type I shift occurs as cYY
binds to CYP121A1, with the Soret band shifting from 416.5 to
393 nm (the cYY KD is 5.82�0.16 μM
[13]). Other features of note
in the spectral titration are apparent isosbestic points at
approximately 420 nm and 492 nm, small red shifts in the alpha
and beta band maxima at ~572 and 547 nm, and loss of the
small high-spin signal at ~650 nm. Coordination binding of
azoles to the CYP121A1 heme iron results in type II (red)
spectral shifts of the Soret peak to wavelengths typically
between ~418–424 nm (according to the specific azole and
whether it binds directly to the heme iron or via a retained
water ligand to the heme iron), accompanied by spectral
changes in both the α and β bands (e.g. 10f, Figure 4).[19]
In Series 1, replacing the phenyl ring of the lead imidazole
compound (1) or triazole compound (2) with a pyridyl ring
resulted in decreased binding affinity compared with the lead
phenyl imidazole (1) and triazole (2) compounds (1 KD=2.6�
0.2 μM c.f. 10a KD=60.5�10.5 μM and 10b KD=53.6�6.8 μM ;
2 KD=73.5�0.7 μM c.f. 11a KD=115.3�27.0 μM and 11b KD=
249.7�51.6 μM) (Table 1).
For the extended pyridyl compounds (13 and 14), low
binding affinity was generally observed, with the exception of
14b which displayed moderate binding affinity (KD=39.0�
8.2 μM). The series 2 imidazole pyrazole regioisomers 23 and 25
displayed moderate binding affinity (KD=34.5�4.8 μM and
22.9�0.2 μM, respectively). However, the triazole pyrazole
Scheme 2. Reagents and Conditions: (i) EtOH, 80 °C, overnight (ii) LiAlH4, THF,
r.t. overnight (iii) SOCl2, CH2Cl2, r.t. overnight (iv) imidazole, K2CO3, CH3CN,
45 °C, 1 h then 70 °C, overnight (v) triazole, K2CO3, CH3CN, 45 °C, 1 h then
70 °C, overnight.
Figure 4. Compound 10f binding to CYP121A1 using UV-Vis optical
binding titration The left-hand panel shows spectra for compound 10f
titrated with CYP121A1 (ligand-free spectrum is a thick black line, spectra
following progressive additions of compound 10 f are thin solid lines, and
the final near-saturated protein spectrum is a thick red line). The inset shows
overlapped difference spectra generated by subtracting the starting
spectrum from each consecutive ligand-bound spectrum. The right-hand
panel shows a plot of compound 10 f induced-absorbance change calculated
as the difference between the peak and trough in the difference spectra in
the left-hand panel, using the same wavelength pair (429 and 392 nm,
respectively). Data was fitted using the Hill equation giving a KD value of
0.22�0.01 μM for 10f.
Table 1. KD and MIC values against M. tuberculosis H37Rv.
Compound KD (μM) Soret peak
shift (nm)
MIC
(μg/mL)
10a 60.5�10.5 416.5 to 419 12.5
10b 53.6�6.8 416.5 to 421 12.5
10c 18.3�3.4 416.5 to 420 1.562
10d 53.7�5.9 416.5 to 420 0.781
10e 22.5�3.5 416.5 to 423 1.562
10f 0.22�0.01 416.5 to 423.5 1.562
10g 4.81�0.31 416.5 to 419.5 1.562
10h 2.91�0.14 416.5 to 423.5 3.125
10 i 10.1�0.3 416.5 to 422.5 3.125
10 j 3.31�0.05 416.5 to 423.5 25
11a 115.3�27.0 416.5 to 417.5 >100
11b 249.7�51.6 416.5 to 417.5 >100
13a 83.2�3.9 416.5 to 423.5 100
13b 85.6�12.4 416.5 to 417.5 >100
14a 218.6�13.6 416.5 to 419.5 >100
14b 39.0�8.2 416.5 to 417.5 >100
23 34.5�4.8 416.5 to 418 >100
24 105�7 416.5 to 418 >100
25 22.9�0.2 416.5 to 418.5 25
26 98.3�7.4 416.5 to 416 100
1 2.6�0.2 416.5 to 424 12.5
2 73.5�0.7 416.5 to 422.5 50
Fluconazole 8.6�0.2 >100
Clotrimazole 0.07�0.01 20
cYY 5.82�0.16 –
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regioisomers 24 and 26 displayed weak binding affinity (KD=
105�7 μM and 98.3�7.4 μM, respectively) (Table 1).
Series 3 biaryl derivatives with branched butyl substitutions
(10f and 10g), the biphenyl substitution (10h) and the indole
substitution (10 j) gave the highest affinity for CYP121A1,
having KD values <5 μM (KD=0.22�0.01 μM, 4.81�0.31 μM,
2.91�0.14 μM and 3.31�0.05 μM, respectively) (Table 1). The
aryl derivatives with shorter alkyl substitutions, 4-ethyl (10c), 4-
propyl (10d), 4-isopropyl (10e) and benzo [d][1,3] dioxole (10 i)
had moderate binding affinity (KD=18.3�3.4 μM, 53.7�5.9 μM,
22.5�3.5 μM, and 10.1�0.3 μM, respectively). The values were
compared with the KD values of fluconazole (8.6�0.2 μM) and
clotrimazole (0.07�0.01 μM).[19]
Compounds 10e, 10f, 10h, 10 i, 10 j and 13a induce the
most extensive Soret absorbance shifts, with the Soret maxima
shifting by 6.5 nm (in the case of 10e) and by 7 nm (in the case
of 10f, 10h, 10 j and 13a). The shifts observed are comparable
with those for azole antifungal drugs (clotrimazole, econazole,
fluconazole, ketoconazole and miconazole), which bind tightly
to Mtb CYP121A1, inducing a Soret peak shift to between 421–
423.5 nm.[20] Less extensive Soret red shifts were observed for
imidazole pyrazole regioisomers (23 and 25), the triazole
pyrazole regioisomers (24 and 26), the 4-ethylbenzene (10c), 4-
propylbenzene (10d) and 4-tert-butylbenzene (10g) and the
Series 1 3-pyridyl and 4-pyridyl (10a and 10b) imidazole
derivatives on binding to the CYP121A1 heme iron.
2.3. MIC Determination Against Mycobacterium Tuberculosis
The derivatives were screened against M. tuberculosis H37Rv by
the REMA (Resazurin Microtiter Assay) method.[21] In Series 1
only the imidazole pyridyl derivatives displayed antimicrobial
activity (10a and 10b, MIC=12.5 μg/mL), retaining the inhib-
itory activity observed for the phenyl imidazole lead compound
(1).
In Series 2 only the 5-((1H-imidazol-1-yl)methyl)-1-(4-me-
thoxyphenyl)-3-methyl-1H-pyrazole (23) displayed antimycobac-
terial activity with an MIC of 25 μg/mL (Table 1). All the
compounds in Series 3 displayed antimycobacterial activity, the
most promising inhibitory activity (MIC=0.781–1.562 μg/mL)
was observed for the alkyl substituted aryl derivatives (10c–
10g). Good inhibitory activity was also obtained for biphenyl
(10h, MIC=3.125 μg/mL) and benzo[d][1,3]dioxole (10 i, MIC=
3.125 μg/mL) derivatives, with the least active in Series 3 being
the 2-chloro-1H-indole derivative (10 j, MIC=25 μg/mL).
Hansch analysis (Figure 5) showed a clear correlation
between the lipophilicity of the compounds and MIC, as
previously observed for the pyrazole lead compounds.[13] This
increased lipophilicity may facilitate increased drug uptake
across the Mtb lipid-rich cell wall resulting in enhanced
antimycobacterial activity. The more lipophilic compounds
10c–10g (cLogP 4.19–4.99) showed the best antimycobacterial
activity (MIC=0.781–1.562 μg/mL), while the more polar pyridyl
(10a and 10b) (cLogP 1.95) and 2-chloro-1H-indole (10 j) (cLogP
3.33) compounds had lower antimycobacterial activity (MIC=
12.5–25 μg/mL).
2.4. Molecular Modelling
The Molecular Operating Environment (MOE) program[22] was
used to perform molecular docking and was found to closely
replicate the position and binding interactions of cYY and
fluconazole, as observed in the crystal structures PDB 3G5H and
PDB 2IJ7, respectively. The 4- and 3-pyridyl derivatives (10/11a
and 10/11b) both interacted with the heme iron through an
interstitial water molecule bonded with Ser237, and the 4-
pyridyl (10a) also formed a direct hydrogen bond with Arg386
(e.g. 10a, Figure 6). Both pyridyl imidazoles (10) and triazoles
(11) formed additional binding interactions through the
pyridine nitrogen, for the 3-pyridyl via a water molecule with
Met62 and for the 4-pyridyl via a water molecule with Met62,
Met86 and Val83 (Figure 6).
The imidazole derivatives (13) with the 5-atom linker
between the imidazole and the pyrazole ring were found to
form more interactions with the CYP121A1 active site compared
with the 4-pyridyl derivatives (14) with the 3-atom linker
between the 4-pyridyl and pyrazole ring. However, the
Figure 5. Hansch analysis illustrating correlation between MIC and calculated
LogP23 values for the Series 1 and 3 imidazole compounds (10).
Figure 6. Series 1 pyridyl compound 10a in CYP121A1 active site. The
imidazole ring interacts with the heme iron through an interstitial water
molecule bonded with Ser237 and a direct hydrogen bond with Arg386.
Additional binding interactions through the pyridine nitrogen are observed
via a water molecule with Met62, Met86 and Val83.
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extended pyridine compounds (13 and 14) were found to form
numerous docking conformations owing to the increased
flexibility of the extended linker between the heme-bonding
group, imidazole for 13 and 4-pyridyl for 14. Series 2 imidazole
(23 and 25) and triazole (24 and 26) derivatives, with the
smaller methyl replacing a phenyl ring, were found to interact
with the heme via an interstitial water molecule bound to
Ser237, and for imidazole 23 a direct hydrogen bond interaction
with Arg386 was formed. Additional hydrophobic interactions
were observed with hydrophobic amino acid residues including
Thr77, Val78, Val82, Val83 and Met86.
The ethyl (10c) and propyl (10d) imidazoles were found to
bind in the same manner through interactions with the heme
iron via an interstitial water molecule linked to Ser237 and with
the phenyl ring interacting with Thr77 via a water molecule.
The isopropyl (10e) and isobutyl (10f) imidazoles interacted
with the heme in the same manner as described for 10c and
10d, but also formed an additional interaction between the
pyrazole ring either with Thr77 via a water molecule in the case
of 10e, or with Gln385 and Arg386 via a water molecule for
10f. The tert-butyl imidazole (10g) and the biphenyl imidazole
(10h) both formed a direct hydrogen bond with Arg386 and
interacted with the heme through an interstitial water molecule
bonded with Ser237. The phenyl ring of the biphenyl imidazole
(10h) also formed an interaction with Thr77 via a water
molecule. The positioning of the additional binding interactions
of the branched alkyl and biphenyl imidazoles (10e–10h)
resulted in a better filling of the binding pocket (Figure 7),
especially in the case of 10f and 10g, and therefore these
compounds would be predicted to be more efficient at blocking
binding of the cYY natural substrate.
The heterobiaryl benzo[d][1,3]dioxole (10 i) and 2-chloro-1H-
indole (10 j) derivatives showed binding of the imidazole with
the heme via an interstitial water molecule through Ser237, and
additional H-bond interactions via Thr77, Arg386 and Gln385.
The more extended pyrazole derivatives (10f, 10g, 10h, 10 i
and 10 j) either formed additional binding interactions and/or
more completely blocked the active site by occupying a similar
binding site as the natural substrate cYY and fluconazole,
resulting in improved binding affinity.
2.5. X-Ray Crystallographic Studies
Two compounds were successful co-crystallized with CYP121A1,
10 j and 14a (PDB 6GEO and 6GEQ respectively). Both crystals
contained two molecules of sulfate resulting from the crystal-
lography process, one of which is positioned above the heme
(Figure 8).
The indole derivative 10 j forms an arene-H interaction
between the imidazole ring and Gln385, and between the
indole benzene ring and Asn85. The indole NH and Cl act as H-
donors with two water molecules and the imidazole N acts as a
H-acceptor with a water molecule. The pyrrole aryl ring is
positioned to form a π-π interaction with Phe168 (Figure 8 A).
Figure 7. Overlapped images of Series 3 ethyl (10c) and isobutyl (10f)
derivatives. The ethyl imidazole (10c, cyan) interacts through the imidazole
with the heme indirectly via an interstitial water molecule bonded to Ser237,
and through the phenyl ring via an interstitial water molecule bonded to
Thr77. The isobutyl imidazole (10f, magenta) interacts with the heme in a
similar manner as observed for 10c, but forms an additional interaction
through the pyrazole ring and occupies the binding site more fully.
Figure 8. X-ray crystal structures of (A) 10 j (PDB 6GEO) and (B) 14a (PDB
6GEQ) binding to CYP121A1. The compounds are shown in cyan and the
haem in orange. Water molecules are illustrated with small red spheres and
amino acids are presented either in light grey or, for amino acids that form
direct or indirect H-bonding interactions with the inhibitor compound, in
magenta. The sulfate molecule from the crystallography process is seen
above the heme and forms H-bond interactions with Arg386 and indirectly
with Ser237.
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The extended 4-pyridyl derivative 14a makes a H-bond
interaction between the carbonyl oxygen and Gln385, and
interacts indirectly with Thr77. Both 4-pyridyl groups form
indirect H-bond interactions: the amide pyridyl with Thr65 and
Arg72, and the pyrrole pyridyl with Val83 and Asn65. The
benzene ring forms an arene-H interaction with Trp182 (Fig-
ure 8B).
Alignment of the crystal structure of 10 j co-crystallized with
CYP121A1 (PDB 6GEO) with the crystal structures of CYP121A1
co-crystallized with fluconazole (PDB 2IJ7) and cYY (PDB 3G5H)
showed a comparable position of all three structures in the
enzyme (Figure 9). All three compounds are positioned to form
a π-π interaction with Phe168 and interact either directly or
indirectly with amino acids Met62, Val83, Asn85. In particular, H-
bonding interactions with Gly385 (10 j and fluconazole) or
Arg386 (cYY) would appear to effectively block access to the
active site.
3. Conclusions
For optimal binding interactions, inhibitors that effectively fill
the CYP121A1 binding site and exhibit strong binding affinity
are those that should most effectively inhibit CYP121A1
substrate (cYY) binding. This is observed for the branched alkyl
derivatives 10f and 10g, and for the biphenyl 10h. Compound
flexibility also has a notable effect, with the extended pyridine
derivatives 13 and 14 displaying very weak binding affinity.
Lipophilicity is a major contributor to antimycobacterial activity,
as shown by Hansch analysis (Figure 5). The challenge in
designing a compound with both good binding affinity and
antimycobacterial activity is to combine the most favourable
properties for each component. The physicochemical properties
of the prepared compounds and reference compounds (cYY,
fluconazole and clotrimazole) were calculated, the cLogP was
determined using Crippen’s fragmentation[23] and the number
of H-bond acceptors (nON), H-bond donors (nOHNH) rotatable
bonds (nrot), along with the molecular volume (MV) and
topological polar surface area (TPSA) were calculated using
Molinspiration software.[24] Those compounds with cLogP >4
and TPSA <40 Å2 had optimal antimycobacterial activity
(shaded green, Table 2), while the compounds with 5–6
rotatable bonds, 4–5 H-bond acceptors, no H-bond donors and
molecular volume >340 Å3 had optimal binding affinity (shaded
red, Table 2).
Therefore, the optimal combined physicochemical proper-
ties for antimycobacterial activity and binding affinity (shaded
green and red, Table 2) identified Series 3 isobutyl (10 f) and
tert-butyl derivatives (10g) as fulfilling these requirements.
These and other high affinity compounds generated in this
study will undergo further testing for their ability to kill
pathogenic strains of M. tuberculosis.
Experimental Section
Chemistry
All reagents and solvents were of general purpose or analytical
grade and purchased from Sigma-Aldrich Ltd, Fisher Scientific, Fluka
and Acros. 1H and 13C NMR spectra were recorded with a Bruker
Avance DPX500 spectrometer operating at 500 and 125 MHz, with
Me4Si as internal standard. Elemental analysis was performed by
MEDAC Ltd (Chobham, Surrey, UK). High resolution mass spectra
(HRMS) were determined at the EPSRC National Mass Spectrometry
Facility at Swansea University and Medac Ltd (Chobham, Surrey,
UK), using ESI (Electrospray Ionisation) in positive and negative
modes, and a TOF (Time-of-Flight) analyser. Flash column chroma-
tography was performed with silica gel 60 (230–400 mesh) (Merck)
and TLC was carried out on precoated silica plates (kiesel gel 60
F254, BDH). Compounds were visualised by illumination under UV
light (254 nm) or by the use of potassium permanganate stain
followed by heating. Melting points were determined on an
Figure 9. Alignment of the crystal structures of CYP121A1 co-crystallized
with 10 j (cyan) (PDB 6GEO), fluconazole (magenta) (PDB 2IJ7) and cYY
(yellow) (PDB 3G5H) with comparable positioning observed.
Table 2. Physiocochemical properties of Series 1, 2 and 3.
Compound cLogP nON/
nOHNH
nrot MV (Å3) TPSA (Å 2)
10a/10b 1.95 5/0 4 273.34 48.54
10c[a] 4.19 4/0 5 310.86 35.65
10d[a] 4.61 4/0 6 327.66 35.65
10e[a] 4.52 4/0 5 327.44 35.65
10f[a,b] 4.94 4/0 6 344.24 35.65
10g[a,b] 4.99 4/0 5 343.68 35.65
10h[b] 4.97 4/0 5 348.90 35.65
10 i 3.07 6/0 4 301.42 54.12
10 j[b] 2.68 5/1 4 306.47 51.44
11a/11b 1.46 6/0 4 269.18 61.44
13a/b 1.26 7/1 7 338.33 77.64
14a/b 1.44 7/1 5 319.36 72.71
23 1.0 5/0 4 248.19 44.89
24 0.5 6/0 4 244.03 57.78
25 0.84 5/0 4 248.19 44.89
26 0.35 6/0 4 244.03 57.78
cYY 1.26 6/4 4 290.68 98.65
Fluconazole 0.87 7/1 5 248.96 81.66
Clotrimazole 5.97 2/0 4 309.52 17.83
[a] Optimal antimycobacterial activity (MIC). [b] Optimal binding affinity
(KD). nON=H-bond acceptor; nOHNH=H-bond donor; nrot=number of
rotatable bonds; MV=molecular volume; TPSA= topological polar surface
area.
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electrothermal instrument and are uncorrected. All solvents were
dried prior to use and stored over 4 Å molecular sieves, under
nitrogen. All the compounds were �95% pure.
The following compounds were prepared as previously described:
hydrazines 6a and 6b,[14] 6h[23] and 6 j;[25] aldehydes 7a and 7b,[14]
7h[26] and 7 j;[25] alcohol 8h;[26] chloride 9h;[26] carboxylic acids (12a)
and (12b);[14] ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-
carboxylate (17) and ethyl 1-(4-methoxyphenyl)-3-methyl-1H-
pyrazole-5-carboxylate (18).[18] All compounds were more than 95%
pure.
General Method for the Preparation of Hydrazine Derivatives
(6)
To a solution of the acetyl reagent (4) (5 mmol) in ethanol (20 mL),
was added acetic acid (3.3 mmol) with continuous stirring at room
temperature. After 5 min, phenylhydrazine (5) (5.5 mmol) was
added dropwise with further stirring for 15 min, then refluxed at
80 °C for 1 h. The reaction was left to cool, concentrated under
reduced pressure, wrapped with aluminium foil and left in the
freezer overnight. The precipitate formed was filtered, washed with
cold ethanol, dried in vacuo and used immediately in subsequent
reactions without further purification.
1-(1-(4-Ethylphenyl)ethylidene)-2-phenylhydrazine (6c)
Prepared from 4-ethylacetophenone (2 mL, 13.39 mmol). Product
obtained as a yellow solid, yield 3.03 g (95%). M.p. 82–84 °C. TLC
(1 :1 petroleum ether/EtOAc), Rf=0.94. 1H NMR (DMSO-d6): δ 9.19
(s, 1H, NH), 7.70 (d, J=8.2 Hz, 2H, Ar), 7.23 (m, 6H, Ar), 6.75 (m, 1H,
para-Ar), 2.61 (q, J=7.6 Hz, 2H, CH2), 2.24 (s, 3H, CH3), 1.19 (t, J=
7.6 Hz, 3H, CH3).
13C NMR (DMSO-d6): δ 146.7 (C=N), 143.6 (C, Ar),
141.2 (C, Ar), 137.3 (C, Ar), 129.3 (2×CH, Ar), 128.1 (2×CH, Ar), 125.7
(2×CH, Ar), 119.2 (CH, para-Ar), 113.2 (2×CH, Ar), 28.3 (CH2), 16.0
(CH3), 13.3 (CH3).
(1-(1-(4-Propylphenyl)ethylidene)-2-phenylhydrazine (6d)
Prepared from 4-propylacetophenone (1 mL, 6.04 mmol). Product
obtained as an orange crystalline solid, yield 1.43 g (92%). M.p. 68–
70 °C. TLC (2 :1 petroleum ether/EtOAc), Rf=0.90. 1H NMR (DMSO-
d6): δ 9.19 (s, 1H, NH), 7.70 (d, J=7.9 Hz, 2H, Ar), 7.23 (m, 6H, Ar),
7.09 (t, J=7.7 Hz, 1H, para-Ar), 2.56 (t, J=7.5 Hz, 2H, CH2), 2.24 (s,
3H, CH3), 1.60 (sext, J=7.3 Hz, 2H, CH2), 0.90 (t, J=7.3 Hz, 3H, CH3).
13C NMR (DMSO-d6): δ 146.7 (C=N), 142.0 (C, Ar), 141.1 (C, Ar), 137.3
(C, Ar), 128.7 (2×CH, Ar), 127.7 (2×CH, Ar), 125.6 (2×CH, Ar), 119.2
(1×CH, para-Ar), 113.2 (2×CH, Ar), 37.4 (CH2), 24.8 (CH2), 14.6 (CH3),
13.3 (CH3).
1-(1-(4-Isopropylphenyl)ethylidene)-2-phenylhydrazine (6e)
Prepared from 4-isopropylacetophenone (2 mL, 11.95 mmol). Prod-
uct obtained as an orange crystalline solid, yield 2.5 g (80%). M.p.
50–52 °C. TLC (1 :1 petroleum ether/EtOAc), Rf=0.93. 1H NMR
(DMSO-d6): δ 9.19 (s, 1H, NH), 7.70 (d, J=7.2 Hz, 2H, Ar), 7.25 (d, J=
7.7 Hz, 2H, Ar), 7.21 (m, 4H, Ar), 6.75 (t, J=6.7 Hz, 1H, para-Ar), 2.90
(m, 1H, CH), 2.24 (s, 3H, CH3), 1.22 (d, J=7.1 Hz, 6H, 2×CH3).
13C
NMR (DMSO-d6): δ 148.3 (C=N), 146.7 (C, Ar), 141.1 (C, Ar), 137.5 (C,
Ar), 129.3 (2×CH, Ar), 126.6 (2×CH, Ar), 125.7 (2×CH, Ar), 119.1
(CH, para-Ar), 113.2 (2×CH, Ar), 33.6 (CH), 24.3 (2×CH3), 13.3 (CH3).
1-(1-(4-Isobutylphenyl)ethylidene)-2-phenylhydrazine (6 f)
Prepared from 4-isobutylacetophenone (5 mL, 27.00 mmol). Product
obtained as an orange solid, yield 6.99 g (97%). M.p. 58–60 °C. TLC
(3 :1 petroleum ether/EtOAc), Rf=0.71. 1H NMR (DMSO-d6): δ 9.18
(s, 1H, NH), 7.69 (d, J=7.7 Hz, 2H, Ar), 7.22 (m, 4H, Ar), 7.16 (d, J=
7.7 Hz, 2H, Ar), 6.75 (t, J=7.3 Hz, 1H, para-Ar), 2.44 (d, J=7.6 Hz, 2H,
CH2), 2.23 (s, 3H, CH3), 1.83 (m, 1H, CH), 0.86 (d, J=7.6 Hz, 6H, 2×
CH3).
13C NMR (DMSO-d6): δ 146.6 (C=N), 141.2 (C, Ar), 141.1 (C, Ar),
137.3 (C, Ar), 129.4 (2×CH, Ar), 129.3 (2×CH, Ar), 125.4 (2×CH, Ar),
119.2 (CH, para-Ar), 113.2 (2×CH, Ar), 44.8 (CH2), 30.0 (CH3), 22.6
(CH), 13.4 (2×CH3).
1-(1-(4-(Tert-butyl)phenyl)ethylidene)-2-phenylhydrazine (6g)
Prepared from 4-(tert-butyl)acetophenone (3 mL, 16.4 mmol). Prod-
uct obtained as an orange crystalline solid, yield 4.2 g (97%). M.p.
66–68 °C. TLC (1 :1 petroleum ether/EtOAc), Rf=0.92. 1H NMR
(DMSO-d6): δ 9.25 (s, 1H, NH), 7.75 (d, J=8.4 Hz, 2H, Ar), 7.40 (d, J=
8.4 Hz, 2H, Ar), 7.31 (m, 4H, Ar), 7.13 (t, J=7.7 Hz, 1H, para-Ar), 2.27
(s, 3H, CH3), 1.31 (s, 9H, 3×CH3).
13C NMR (DMSO-d6): δ 150.4 (C=N),
146.7 (C, Ar), 141.1 (C, Ar), 137.1 (C, Ar), 129.3 (2×CH, Ar), 129.0 (2×
CH, Ar), 125.4 (2×CH, Ar), 119.2 (CH, para-Ar), 113.3 (2×CH, Ar),
34.7 (C(CH3)3), 31.5 (3×CH3), 13.3 (CH3).
1-(1-(Benzo[d][1,3]dioxol-5-yl)ethylidene)-2-phenylhydrazine
(6 i)
Prepared from 3',4'-(methylenedioxy)acetophenone (3.00 g,
18.27 mmol). Product obtained as a yellow solid, yield 3.90 g (84%).
M.p. 66–68 °C. TLC (1 :1 petroleum ether/EtOAc), Rf=0.88. 1H NMR
(DMSO-d6): δ 9.14 (s, 1H, NH), 7.40 (s, 1H, benzo[d][1,3]dioxole), 7.23
(d, J=1.6 Hz, 1H, benzo[d][1,3]dioxole), 7.21 (m, 4H, Ar), 6.92 (d, J=
8.6 Hz, 1H, benzo[d][1,3]dioxole), 6.74 (t, J=4.1 Hz, 1H, para-Ar),
6.04 (s, 2H, benzo[d][1,3]dioxole), 2.21 (s, 3H, CH3).
13C NMR (DMSO-
d6): δ 148.0 (C=N), 147.5 (C, benzo[d][1,3]dioxole), 146.7 (C, benzo[d]
[1,3]dioxole), 140.9 (C, Ar), 134.3 (C, Ar), 134.3 (C, Ar), 129.3 (2×CH,
Ar), 119.7 (CH, para-Ar), 119.1 (CH, benzo[d][1,3]dioxole), 113.2 (CH,
benzo[d][1,3]dioxole), 108.3 (2×CH, Ar), 105.6 (C, benzo[d][1,3]
dioxole), 101.5 (CH2, benzo[d][1,3]dioxole), 13.5 (CH3).
General Method for the Preparation of Aldehyde Derivatives
(7)
Phosphorus (V) oxychloride (15 mmol) was added dropwise to an
ice-cooled solution of hydrazine (6) (5 mmol) in dry DMF (50 mL).
The reaction mixture was allowed to reach room temperature, and
then heated at 60 °C for 4 h with continuous stirring. The resulting
mixture was poured onto crushed ice (50 mL), brought to pH 8.0
using 10% aqueous NaOH (�50 mL), and left overnight in the
freezer. The resulting precipitate was extracted with EtOAc (100 mL)
and the organic layer was washed with brine (5×50 mL), while the
aqueous phase was re-extracted with EtOAc (3×50 mL). The
combined organic fractions were washed with brine (3×50 mL),
dried (MgSO4) and evaporated in vacuo to obtain the crude
product, which was purified by gradient column chromatography.
3-(4-Ethylphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (7c)
Prepared from 1-(1-(4-ethylphenyl)ethylidene)-2-phenylhydrazine
(6c) (2.5 g, 10.48 mmol). The product was eluted with petroleum
ether – EtOAc 85 :15 v/v to give the product as a buff solid, yield
1.76 g (61%). M.p. 112–114 °C. TLC (1 :1 petroleum ether/EtOAc),
Rf=0.88. 1H NMR (DMSO-d6): δ 9.99 (s, 1H, CHO), 9.31 (s, 1H,
pyrazole), 8.00 (d, J=7.6 Hz, 2H, Ar), 7.86 (d, J=8.1 Hz, 2H, Ar), 7.58
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(t, J=7.5 Hz, 2H, Ar), 7.43 (t, J=7.5 Hz, 1H, para-Ar), 7.36 (d, J=
8.3 Hz, 2H, Ar), 2.69 (q, J=7.6 Hz, 2H, CH2), 1.24 (t, J=7.6 Hz, 3H,
CH3).
13C NMR (DMSO-d6): δ 185.0 (CHO), 153.4 (C, pyrazole), 145.4
(C, Ar), 139.1 (C, Ar), 135.1 (CH, pyrazole), 130.1 (2×CH, Ar), 129.1
(2×CH, Ar), 128.5 (2×CH, Ar), 128.3 (CH, para-Ar), 122.7 (C,
pyrazole), 122.6 (C, Ar), 119.8 (2×CH, Ar), 28.4 (CH2), 16.0 (CH3).
Anal. Calcd for C18H16N2O (276.3372): C, 78.24; H, 5.84; N, 10.13.
Found: C, 78.11; H, 5.84; N, 10.13.
1-Phenyl-3-(4-propylphenyl)-1H-pyrazole-4-carbaldehyde (7d)
Prepared from 1-(1-(4-propylphenyl)ethylidene)-2-phenylhydrazine
(6d) (1.20 g, 4.75 mmol). The product was eluted with petroleum
ether – EtOAc 85 :15 v/v to give the product as a white solid, yield
0.91 g (66%). M.p. 86–88 °C. TLC (3 :1 petroleum ether/EtOAc), Rf=
0.68. 1H NMR (DMSO-d6): δ 9.99 (s, 1H, CHO), 9.31 (s, 1H, pyrazole),
8.00 ( d, J=7.6 Hz, 2H, Ar), 7.85 (d, J=7.8 Hz, 2H, Ar), 7.58 (t, J=
7.5 Hz, 2H, Ar), 7.43 (t, J=7.5 Hz, 1H, para-Ar), 7.34 (d, J=7.8 Hz, 2H,
Ar), 2.63 (t, J=7.4 Hz, 2H, CH2), 1.65 (sext, J=7.3 Hz, 2H, CH2), 0.93
(t, J=7.4 Hz, 3H, CH3).
13C NMR (DMSO-d6): δ 185.0 (CHO), 153.2 (C,
pyrazole), 143.9 (C, Ar), 139.1 (C, Ar), 135.2 (CH, pyrazole), 130.2 (2×
CH, Ar), 130.1 (C, Ar), 129.2 (2×CH, Ar), 129.1 (2×CH, Ar), 128.2 (CH,
para-Ar), 122.6 (C, pyrazole), 119.7 (2×CH, Ar), 37.5 (CH2), 24.5 (CH2),
14.1 (CH3). Anal. Calcd for C19H18N2O (290.364): C, 78.59; H, 6.25; N,
9.64. Found: C, 78.37; H, 6.36; N, 9.68.
3-(4-(Isopropylphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde
(7e)
Prepared from 1-(1-(4-isopropylphenyl)ethylidene)-2-phenylhydra-
zine (6e) (2.30 g, 9.24 mmol). The product was eluted with
petroleum ether – EtOAc 85 :15 v/v to give the product as a white
solid, yield 2.30 g (78%). M.p. 114–116 °C. TLC (1 :1 petroleum
ether/EtOAc), Rf=0.83. 1H NMR (DMSO-d6): δ 9.99 (s, 1H, CHO), 9.31
(s, 1H, pyrazole), 8.01 (d, J=7.6 Hz, 2H, Ar), 7.86 (d, J=8.1 Hz, 2H,
Ar), 7.58 (t, J=8.2 Hz, 2H, Ar), 7.43 (t, J=8.3 Hz, 1H, para-Ar), 7.39
(d, J=8.2 Hz, 2H, Ar), 2.97 (sept, J=6.8 Hz, 1H, CH), 1.26 (d, J=
6.9 Hz, 6H, 2×CH3).
13C NMR (DMSO-d6): δ 185.2 (CHO), 153.2 (C,
pyrazole), 150.1 (C, Ar), 139.1 (C, Ar), 135.2 (CH, pyrazole), 130.2 (2×
CH, Ar), 129.3 (C, Ar), 129.2 (2×CH, Ar), 128.2 (CH, para-Ar), 127.0
(2×CH, Ar), 122.6 (1 C, pyrazole), 119.7 (2×CH, Ar), 33.8 (CH), 24.3
(2×CH3). Anal. Calcd for C19H18N2O (290.364): C, 78.59; H, 6.25; N,
9.64. Found: C, 78.42; H, 6.15; N, 9.58.
3-(4-Isobutylphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde
(7 f)
Prepared from 1-(1-(4-isobutylphenyl)ethylidene)-2-phenylhydra-
zine (6f) (6.00 g, 22.52 mmol). The product was eluted with
petroleum ether – EtOAc 4 :1 v/v to give the product as a yellow oil,
yield 4.82 g (70%). TLC (3 :1 petroleum ether/EtOAc), Rf=0.38. 1H
NMR (DMSO-d6): δ 9.98 (s, 1H, CHO), 9.27 (s, 1H, pyrazole), 7.97 (d,
J=7.8 Hz, 2H, Ar), 7.84 (d, J=7.7 Hz, 2H, Ar), 7.57 (t, J=7.7 Hz, 2H,
Ar), 7.42 (t, J=7.6 Hz, 1H, para-Ar), 7.28 (d, J=7.8 Hz, 2H, Ar), 2.51
(d, J=6.8 Hz, 2H, CH2), 1.88 (m, 1H, CH), 0.88 (d, J=6.7 Hz, 6H, 2×
CH3).
13C NMR (DMSO-d6): δ 185.0 (CHO), 153.1 (C, Ar), 142.8 (C,
pyrazole), 139.1 (C, Ar), 135.4 (CH, pyrazole), 130.2 (2×CH, Ar), 129.6
(2×CH, Ar), 129.2 (C, Ar), 128.9 (2×CH, Ar), 128.2 (CH, para-Ar),
122.6 (C, pyrazole), 119.7 (2×CH, Ar), 44.8 (CH2), 30.1 (CH), 22.6 (2×
CH3). [ESI-HRMS] calculated for C20H21N2O: 305.1648 [M+H]
+.
Found: 305.1651 [M+H]+.
3-(4-(Tert-butyl)phenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde
(7g)
Prepared from 1-(1-(4-(tert-butyl)phenyl)ethylidene)-2-phenylhydra-
zine (6g) (3.50 g, 13.13 mmol). The product was eluted with
petroleum ether – EtOAc 4 :1 v/v to give the product as a yellow
solid, yield 3.24 g (81%). M.p. 96–98 °C. TLC (3 :1 petroleum ether/
EtOAc), Rf=0.18. 1H NMR (DMSO-d6): δ 10.01 (s, 1H, CHO), 9.30 (s,
1H, pyrazole), 8.00 (d, J=7.6 Hz, 2H, Ar), 7.87 (d, J=8.3 Hz, 2H, Ar),
7.56 (t, J=8.2 Hz, 2H, Ar), 7.51 (d, J=8.4 Hz, 2H, Ar), 7.35 (t, J=
7.6 Hz, 1H, para-Ar), 1.31 (s, 9H, 3×CH3).
13C NMR (DMSO-d6):
δ 185.1 (CHO), 153.2 (C, Ar), 152.2 (C, pyrazole), 139.1 (C, Ar), 135.1
(CH, pyrazole), 130.2 (2×CH, Ar), 129.0 (C, pyrazole), 128.9 (2×CH,
Ar), 128.1 (CH, para-Ar), 125.8 (2×CH, Ar), 122.6 (C, pyrazole), 119.7
(2×CH, Ar), 34.9 (C(CH3)3), 31.5 (3×CH3). [ESI-HRMS] calculated for
C20H21N2O: 305.1648 [M+H]
+. Found: 305.1652 [M+H]+.
3-(Benzo[d][1,3]
dioxol-5-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde (7 i)
Prepared from1-(1-(benzo[d][1,3]dioxol-5-yl)ethylidene)-2-phenylhy-
drazine (6 i) (1.62 g, 6.37 mmol). The product was eluted with
petroleum ether – EtOAc 7 :1 v/v to give the product as a yellow
solid, yield 1.50 g (81%). M.p. 167–169 °C. TLC (1 :1 petroleum
ether/EtOAc), Rf=0.94. 1H NMR (DMSO-d6): δ 9.96 (s, 1H, CHO), 9.31
(s, 1H, pyrazole), 7.99 (d, J=7.7 Hz, 2H, Ar), 7.57 (t, J=7.6 Hz, 2H,
Ar), 7.53 (s, 1H, benzo[d][1,3]dioxole), 7.51 (d, J=1.6 Hz, 1H, benzo
[d][1,3]dioxole), 7.43 (t, J=7.4 Hz, 1H, para-Ar), 7.05 (d, J=8.6 Hz,
1H, benzo[d][1,3]dioxole), 6.11 (s, 2H, benzo[d][1,3]dioxole). 13C NMR
(DMSO-d6): δ 185.0 (CHO), 152.7 (C, pyrazole), 148.6 (C, benzo[d]
[1,3]dioxole), 147.9 (C, benzo[d][1,3] dioxole), 139.0 (C, Ar), 135.8
(CH, pyrazole), 130.2 (2×CH, Ar), 128.1 (CH, para-Ar), 125.6 (C,
benzo[d][1,3]dioxole), 123.4 (CH, benzo[d][1,3]dioxole), 122.4 (C,
pyrazole), 119.7 (2×CH, Ar), 109.2 (CH, benzo[d][1,3]dioxole), 108.9
(CH, benzo[d][1,3]dioxole), 101.8 (CH2, benzo[d][1,3]dioxole). [ESI-
HRMS] calculated for C17H13N2O3: 293.0924 [M+H]
+. Found:
293.0921 [M+H]+.
General Method for the Preparation of Alcohol Derivatives (8)
To an ice-cooled solution of carbaldehyde (7) (1 mmol) in EtOH
(10 mL) was added NaBH4 (1 mmol) in portions, then the reaction
was then stirred at room temperature for 1 h. The solvent was
evaporated and H2O (20 mL) was added slowly and the reaction
stirred for 30 min. The reaction mixture was extracted with EtOAc
(2×25 mL), then the combined organic layers washed with H2O (3×
25 mL), dried (MgSO4) and evaporated under reduced pressure to
give the crude alcohol (17), which was was further purified by
gradient column chromatography.
(1-Phenyl-3-(pyridin-4-yl)-1H-pyrazol-4-yl)methanol (8a)
Prepared from 1-phenyl-3-(pyridin-4-yl)-1H-pyrazole-4-carbaldehyde
(7a)[14] (0.40 g, 1.6 mmol). The product was obtained as a light
yellow solid pure enough for use in the following reaction. Yield
0.33 g (82%). M.p. 120–122 °C. TLC (1 :4 petroleum ether/EtOAc),
Rf=0.22. 1H NMR (DMSO-d6): δ 8.66 (d, J=6.0 Hz, 2H, pyridine), 8.58
(s, 1H, pyrazole), 7.90 (d, J=7.7 Hz, 2H, Ar), 7.85 (d, J=6.0 Hz, 2H,
pyridine), 7.54 (d, J=7.6 Hz, 2H, Ar), 7.36 (t, J=7.4 Hz, 1H, para-Ar),
5.34 (t, J=5.0 Hz, 1H, OH ex), 4.63 (d, J=5.0 Hz, 2H, CH2).
13C NMR
(DMSO-d6): δ 150.5 (2×CH, pyridine), 148.2 (C, Ar), 140.5 (C, Ar),
139.8 (C, Ar), 130.1 (2×CH, Ar), 129.8 (CH, Ar), 127.1 (CH, Ar), 123.5
(C, Ar), 122.0 (2×CH, Ar), 118.9 (2×CH, Ar), 54.3 (CH2). [ESI-HRMS]
calculated for C15H14N3O: 252.1137 [M+H]
+. Found: 252.1136 [M+
H]+.
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(1-Phenyl-3-(pyridin-3-yl)-1H-pyrazol-4-yl)methanol (8b)
Prepared from 1-phenyl-3-(pyridin-3-yl)-1H-pyrazole-4-carbaldehyde
(7b)[14] (1.00 g, 4.03 mmol). The product was obtained as a light
yellow solid pure enough for use in the following reaction. Yield
0.85 g (85%). M.p. 111–113 °C. TLC (1 :4 petroleum ether/EtOAc),
Rf=0.23. 1H NMR (DMSO-d6): δ 9.09 (s, 1H, pyridine), 8.60 (d, J=
6.4 Hz, 1H, pyridine), 8.58 (s, 1H, pyrazole), 8.28 (d, J=8.2 Hz, 1H,
pyridine), 7.92 (d, J=7.6 Hz, 2H, Ar), 7.53 (m, 3H, 1×pyridine, 2×Ar),
7.34 (t, J=7.4 Hz, 1H, para-Ar), 5.27 (t, J=5.0 Hz, 1H, OH ex), 4.58 (d,
J=5.0 Hz, 2H, CH2).
13C NMR (DMSO-d6): δ 149.0 (CH, pyridine),
148.2 (CH, pyridine), 174.6 (C, Ar), 139.3 (C, pyrazole), 135.1 (CH,
pyridine), 128.9 (2×CH, Ar), 128.2 (C, pyrazole), 128.0 (CH, pyridine),
126.5 (2×CH, Ar), 124.0 (CH, para-Ar), 119.0 (CH, pyrazole), 116.7 (C,
pyridine), 54.3 (CH2). [ESI-HRMS] calculated for C15H14N3O: 252.1137
[M+H]+. Found: 252.1134 [M+H]+.
(3-(4-Ethylphenyl)-1-phenyl-1H-pyrazol-4-yl)methanol (8c)
Prepared from 3-(4-ethylphenyl)-1-phenyl-1H-pyrazole-4-carbalde-
hyde (7c) (1.68 g, 6.07 mmol). The product was eluted with
petroleum ether – EtOAc 7 :3 v/v to give the product as a white
solid, yield 0.86 g (51%). M.p. 54–55 °C. TLC (1 :1 petroleum ether/
EtOAc), Rf=0.71. 1H NMR (DMSO-d6): δ 8.48 (s, 1H, pyrazole), 7.89
(d, J=7.5 Hz, 2H, Ar), 7.81 (d, J=8.0 Hz, 2H, Ar), 7.51 (t, J=7.5 Hz,
1H, para-Ar), 7.30 (m, 4H, Ar), 5.22 (t, J=5.1 Hz, 1H, OH ex), 4.56 (d,
J=4.9 Hz, 2H, CH2), 2.65 (q, J=7.5 Hz, 2H, CH2), 1.22 (t, J=7.5 Hz,
3H, CH3).
13C NMR (DMSO-d6): δ 150.9 (C, pyrazole), 144.0 (C, Ar),
140.0 (C, Ar), 130.9 (C, Ar), 130.0 (2×CH, Ar), 129.1 (CH, para-Ar),
128.4 (2×CH, Ar), 127.8 (2×CH, Ar), 126.5 (CH, pyrazole), 125.8 (C,
pyrazole), 118.5 (2×CH, Ar), 54.6 (CH2), 28.4 (CH2), 16.0 (CH3). [ESI-
HRMS] calculated for C18H19N2O: 279.1497 [M+H]
+. Found:
279.1503 [M+H]+.
(1-Phenyl-3-(4-propylphenyl)-1H-pyrazol-4-yl)methanol (8d)
Prepared from 1-phenyl-3-(4-propylphenyl)-1H-pyrazole-4-carbalde-
hyde (7d) (0.80 g, 2.75 mmol). The product was eluted with
petroleum ether – EtOAc 7 :3 v/v to give the product as a yellow
solid, yield 0.74 g (92%). M.p. 86–88 °C. TLC (2 :1 petroleum ether/
EtOAc), Rf=0.48. 1H NMR (DMSO-d6): δ 8.49 (s, 1H, pyrazole), 7.89
(d, J=7.6 Hz, 2H, Ar), 7.80 (d, J=7.5 Hz, 2H, Ar), 7.51 (t, J=7.1 Hz,
1H, para-Ar), 7.31 (d, J=7.3 Hz, 2H, Ar), 7.29 (d, J=8.1 Hz, 2H, Ar),
5.18 (t, J=5.0 Hz, 1H, OH ex), 4.55 (d, J=4.9 Hz, 2H, CH2), 2.61 (t, J=
7.4 Hz, 2H, CH2), 1.64 (sext, J=7.2 Hz, 2H, CH2), 0.93 (t, J=7.3 Hz,
3H, CH3).
13C NMR (DMSO-d6): δ 150.8 (C, pyrazole), 142.3 (C, Ar),
140.0 (C, Ar), 130.9 (C, Ar), 130.0 (2×CH, Ar), 129.1 (2×CH, Ar), 129.0
(CH, para-Ar), 127.7 (2×CH, Ar), 126.5 (CH, pyrazole), 122.3 (C,
pyrazole), 118.5 (2×CH, Ar), 54.6 (CH2), 37.5 (CH2), 24.5 (CH2), 14.1
(CH3). [ESI-HRMS] calculated for C19H21N2O: 293.1654 [M+H]
+.
Found: 293.1654 [M+H]+.
(1-Phenyl-3-(4-isopropylphenyl)-1H-pyrazol-4-yl)methanol
(8e)
Prepared from 1-phenyl-3-(4-isopropylphenyl)-1H-pyrazole-4-carbal-
dehyde (7e) (0.90 g, 3.09 mmol). The product was eluted with
petroleum ether – EtOAc 7 :3 v/v to give the product as a colourless
oil, yield 0.76 g (84%). TLC (1 :1 petroleum ether/EtOAc), Rf=0.67.
1H NMR (DMSO-d6): δ 8.49 (s, 1H, pyrazole), 7.90 (d, J=7.6 Hz, 2H,
Ar), 7.82 (d, J=8.1 Hz, 2H, Ar), 7.51 (t, J=8.3 Hz, 2H, Ar), 7.35 (d, J=
8.1 Hz, 2H, Ar), 7.31 (m, 1H, para-Ar), 5.18 (t, J=4.9 Hz, 1H, OH ex),
4.57 (d, J=4.8 Hz, 2H, CH2), 2.94 (sept, J=6.8 Hz, 1H, CH), 1.25 (d,
J=6.9 Hz, 6H, 2×CH3).
13C NMR (DMSO-d6): δ 150.8 (C, pyrazole),
148.5 (C, Ar), 140.0 (C, Ar), 131.1 (C, Ar), 130.0 (2×CH, Ar), 129.1 (CH,
para-Ar), 127.8 (2×CH, Ar), 126.9 (2×CH, Ar), 126.4 (CH, pyrazole),
122.4 (C, pyrazole), 118.5 (2×CH, Ar), 54.6 (CH2), 33.7 (CH), 24.3 (2×
CH3). Anal. Calcd for C19H20N2O (292.3798): C, 78.92; H, 6.62; N, 9.20.
Found: C, 78.63; H, 6.68; N, 9.13.
(3-(4-Isobutylphenyl)-1-phenyl-1H-pyrazol-4-yl)methanol (8 f)
Prepared from 1-phenyl-3-(4-isobutylphenyl)-1H-pyrazole-4-carbal-
dehyde (7f) (4.00 g, 13.13 mmol). The product was obtained as a
greenish brown oil pure enough for use in the following reaction.
Yield 3.67 g (91%). TLC (3 :1 petroleum ether/EtOAc), Rf=0.18. 1H
NMR (DMSO-d6): δ 8.32 (s, 1H, pyrazole), 7.82 (d, J=7.9 Hz, 2H, Ar),
7.64 (d, J=7.8 Hz, 2H, Ar), 7.55 (t, J=7.7 Hz, 2H, Ar), 7.43 (t, J=
7.7 Hz, 1H, para-Ar), 7.26 (d, J=7.9 Hz, 2H, Ar), 5.16 (t, J=5.0 Hz, 1H,
OH ex), 4.56 (d, J=4.9 Hz, 2H, CH2), 2.49 (d, J=6.8 Hz, 2H, CH2), 1.90
(m, 1H, CH), 0.89 (d, J=6.8 Hz, 6H, 2×CH3).
13C NMR (DMSO-d6):
δ 150.7 (C, pyrazole), 141.5 (C, Ar), 139.9 (C, Ar), 130.9 (C, Ar), 130.0
(2×CH, Ar), 129.6 (2×CH, Ar), 129.0 (CH, para-Ar), 127.6 (2×CH, Ar),
126.5 (CH, pyrazole), 122.3 (C, pyrazole), 118.5 (2×CH, Ar), 54.6
(CH2), 44.8 (CH2), 30.1 (CH), 22.6 (2×CH3). [ESI-HRMS] calculated for
C20H23N2O: 307.1809 [M+H]
+. Found: 307.1805 [M+H]+.
(1-Phenyl-3-(4-tert-butylphenyl)-1H-pyrazol-4-yl)methanol
(8g)
Prepared from 1-phenyl-3-(4-(tert-butylphenyl)-1H-pyrazole-4-car-
baldehyde (7g) (2.3 g, 7.55 mmol). The product was eluted with
petroleum ether – EtOAc 3 :1 v/v to give the product as a yellow
solid, yield 2.0 g (87%). M.p. 92–94 °C. TLC (1 :1 petroleum ether/
EtOAc), Rf=0.73. 1H NMR (DMSO-d6): δ 8.49 (s, 1H, pyrazole), 7.89
(d, J=7.6 Hz, 2H, Ar), 7.82 (d, J=8.4 Hz, 2H, Ar), 7.50 (m, 4H, Ar),
7.31 (t, J=7.4 Hz, 1H, para-Ar), 5.18 (t, J=4.9 Hz, 1H, OH ex), 4.57 (d,
J=4.7 Hz, 2H, CH2), 1.33 (s, 9H, 3×CH3).
13C NMR (DMSO-d6): δ 150.8
(C, pyrazole), 140.04 (2×C, Ar), 130.7 (C, Ar), 130.0 (2×CH, Ar), 129.1
(2×CH, Ar), 127.6 (CH, para-Ar), 126.5 (2×CH, Ar), 125.8 (CH,
pyrazole), 122.4 (C, pyrazole), 118.5 (2×CH, Ar), 54.6 (CH2), 34.8 (C
(CH3)3), 31.6 (3×CH3). [ESI-HRMS] calculated for C20H23N2O: 307.1805
[M+H]+. Found: 307.1797 [M+H]+.
(3-(Benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-yl)
methanol (8 i)
Prepared from 3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazole-4-
carbaldehyde (7 i) (1.40 g, 4.78 mmol). The product was eluted with
petroleum ether – EtOAc 65 :35 v/v to give the product as a yellow
solid, yield 1.06 g (75%). M.p. 96–98 °C. TLC (1 :1 petroleum ether/
EtOAc), Rf=0.38. 1H NMR (DMSO-d6): δ 8.48 (s, 1H, pyrazole), 7.88
(d, J=7.7 Hz, 2H, Ar), 7.51 (t, J=7.3 Hz, 2H, Ar), 7.47 (s, 1H, benzo[d]
[1,3]dioxole), 7.41 (d, J=1.6 Hz, 1H, benzo[d][1,3]dioxole), 7.30 (t,
J=7.2 Hz, 1H, para-Ar), 7.02 (d, J=7.9 Hz, 1H, benzo[d][1,3]dioxole),
6.08 (s, 2H, benzo[d][1,3]dioxole), 5.21 (br s, 1H, OH ex), 4.53 (d, 2H,
J=4.0 Hz, CH2).
13C NMR (DMSO-d6): δ 150.7 (C, pyrazole), 148.0 (C,
benzo[d][1,3]dioxole), 147.5 (C, benzo[d][1,3]dioxole), 140.0 (C, Ar),
130.0 (2×CH, Ar), 129.2 (CH, para-Ar), 127.5 (C, benzo[d][1,3]
dioxole), 126.5 (CH, pyrazole), 121.9 (C, pyrazole), 121.7 (CH, benzo
[d][1,3]dioxole), 118.8 (2×CH, Ar), 108.9 (CH, benzo[d][1,3]dioxole),
108.1 (CH, benzo[d][1,3]dioxole), 101.6 (CH2, benzo[d][1,3]dioxole),
54.5 (CH2). [ESI-HRMS] calculated for C17H15N2O3: 295.1077 [M+H]
+.
Found: 295.1077 [M+H]+.
(3-(1H-Indol-3-yl)-1-phenyl-1H-pyrazol-4-yl)methanol (8 j)
Prepared from 3-(1H-indol-3-yl)-1-phenyl-1H-pyrazole-4-carbalde-
hyde (7j)[25] (8.00 g, 27.84 mmol). The product was eluted with
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petroleum ether – EtOAc 45 :55 v/v to give the product as a brown
waxy solid, yield 5.42 g (67%). TLC (1 :2 petroleum ether/EtOAc),
Rf=0.47. 1H NMR (DMSO-d6): δ 11.38 (NH, indole), 8.48 (s, 1H,
indole), 8.43 (d, J=7.2 Hz, 1H, indole), 7.96 (d, J=7.6 Hz, 2H, Ar),
7.90 (s, 1H, pyrazole), 7.54 (t, J=7.9 Hz, 2H, Ar), 7.49 (d, J=7.3 Hz,
1H, indole), 7.28 (t, J=7.4 Hz, 1H, para-Ar), 7.19 (m, 2H, indole), 5.19
(t, J=5.1 Hz, 1H, OH ex), 4.64 (d, J=4.8 Hz, 2H, CH2).
13C NMR
(DMSO-d6): δ 148.1 (C, Ar), 140.3 (C, indole), 136.8 (C, pyrazole),
130.0 (2×CH, Ar), 127.6 (CH, indole), 126.0 (C, indole), 125.8 (CH,
para-Ar), 122.2 (CH, pyrazole), 122.1 (CH, indole), 121.8 (C, pyrazole),
120.1 (CH, indole), 117.9 (2×CH, Ar), 112.0 (2×CH, indole), 108.6 (C,
indole), 55.0 (CH2). [ESI-HRMS] calculated for C18H16N3O: 290.1293
[M+H]+. Found: 290.1295 [M+H]+.
General Method for the Preparation of Alcohol Derivatives
(19) and (20)
To an ice-cooled solution of ethyl carboxylate (17 or 18)[18] (5 mmol)
in dry THF (15 mL) was added LiAlH4 (1 M in THF, 7.5 mmol)
dropwise over 25 min. The reaction was then stirred at room
temperature overnight then cooled in an ice-bath and carefully
quenched with H2O until cessation of effervescence. The reaction
mixture was extracted with EtOAc (2×50 mL), then the combined
organic layers washed with H2O (3×50 mL), dried (MgSO4) and
evaporated under reduced pressure to give the crude alcohol (5) or
(6) which was was further purified by recrystallisation from CH2Cl2-
hexane 1 :1 v/v.
1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)methanol (19)
Prepared from ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-
carboxylate[18] (17) (1.90 g, 7.18 mmol). Product obtained as a
brown solid, yield 1.02 g (64%). M.p. 115–118 °C. TLC (1 :1 hexane/
EtOAc), Rf=0.21. 1H NMR (DMSO-d6): δ 7.33 (d, J=8.9 Hz, 2H, Ar),
6.87 (d, J=8.9 Hz, 2H, Ar), 6.06 (s, 1H, pyrazole), 4.99 (t, J=5.8 Hz,
1H, ex), 4.39 (d, J=5.7 Hz, 2H, CH2), 3.78 (s, 3H, OCH3), 2.24 (s, 3H,
CH3).
13C-NMR (DMSO-d6): δ 158.0 (C, Ar), 147.2 (C, pyrazole), 143.6
(C, pyrazole), 133.8 (C, Ar), 123.5 (2×CH, Ar), 114.3 (2×CH, Ar), 106.3
(CH, pyrazole), 55.7 (OCH3), 53.0 (CH2), 12.1 (CH3). Anal. Calcd for
C12H14N2O2 · 1H2O (220.0563): C, 65.49; H, 6.50; N, 12.73. Found: C,
65.54; H, 6.37; N, 12.83.
1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5-yl)methanol (20)
Prepared from ethyl 1-(4-methoxyphenyl)-3-methyl-1H-pyrazole-5-
carboxylate[18] (18) (1.50 g, 5.67 mmol). Product obtained as a
brown solid, yield 0.82 g (66%). M.p. 103–105 °C. TLC (1 :1 hexane/
EtOAc), Rf=0.43. 1H NMR (CDCl3): δ 7.39 (d, J=9.0 Hz, 2H, Ar), 7.05
(d, J=8.9 Hz, 2H, Ar), 6.19 (s, 1H, pyrazole), 5.02 (t, J=5.8 Hz, 1H,
ex), 4.41 (d, J=5.7 Hz, 2H, CH2), 3.82 (s, 3H, OCH3), 2.26 (s, 3H, CH3).
13C-NMR (CDCl3): δ 158.6 (C, Ar), 147.8 (C, pyrazole), 144.0 (C,
pyrazole), 133.8 (C, Ar), 125.5 (2×CH, Ar), 114.6 (2×CH, Ar), 107.3
(CH, pyrazole), 55.9 (OCH3), 54.6 (CH2), 12.2 (CH3). Anal. Calcd for
C12H14N2O2 (218.2548): C, 66.04; H, 6.47; N, 12.83. Found: C, 65.80; H,
6.41; N, 12.68.
General Method for the Preparation of Chlorides (9), (21) and
(22)
To an ice-cooled solution of alcohol (8 or 19 or 20) (1 mmol) in dry
CH2Cl2 (5 mL) was added thionyl chloride (10 mmol) dropwise over
25 min. The reaction was stirred at room temperature overnight
and then cooled in an ice-bath and carefully quenched with
saturated aqueous NaHCO3 in portions until slightly basic (pH 8.0).
The organic layer was separated, washed with brine (3×10 mL),
H2O (2×10 mL), dried (MgSO4) and evaporated under reduced
pressure to give the crude chloride, which was was purified by
petroleum ether – EtOAc gradient column chromatography.
4-(4-(Chloromethyl)-1-phenyl-1H-pyrazol-3-yl)Pyridine (9a)
Prepared from (1-phenyl-3-(pyridine-4-yl)-1H-pyrazol-4-yl)methanol
(8a) (0.19 g, 0.75 mmol). The product was obtained as a brown
solid that was used immediately in the next step without further
purification owing to instability. Yield 0.19 g (75%). M.p. 78–80 °C.
TLC (1 :4 petroleum ether/EtOAc), Rf=0.56. 1H NMR (DMSO-d6):
δ 8.81 (s, 1H, pyrazole), 8.72 (d, J=7.3 Hz, 2H, pyridine), 7.91 (d, J=
7.7 Hz, 2H, Ar), 7.85 (d, J=7.2 Hz, 2H, pyridine), 7.56 (d, J=7.6 Hz,
2H, Ar), 7.39 (t, J=7.4 Hz, 1H, para-Ar), 5.00 (s, 2H, CH2).
13C NMR
(DMSO-d6): δ 150.5 (2×CH, pyridine), 147.4 (C, Ar), 144.5 (C, Ar),
138.9 (C, Ar), 130.2 (2×CH, Ar), 128.5 (CH, Ar), 124.5 (CH, Ar), 122.4
(2×CH, Ar), 119.6 (2×CH, Ar), 116.2 (C, Ar), 37.9 (CH2).
3-(4-(Chloromethyl)-1-phenyl-1H-pyrazol-3-yl)Pyridine (9b)
Prepared from (1-phenyl-3-(pyridine-3-yl)-1H-pyrazol-4-yl)methanol
(8b) (0.87 g, 3.49 mmol). The product was obtained as a pale
orange solid that was used immediately in the next step without
further purification owing to instability. Yield 0.8 g (85%). M.p. 52 °C
(decomp.). TLC (1 :4 petroleum ether/EtOAc), Rf=0.76. 1H NMR
(DMSO-d6): δ 9.14 (s, 1H, pyridine), 8.75 (d, J=6.5 Hz, 1H, pyridine),
8.67 (s, 1H, pyrazole), 8.52 (d, J=8.1 Hz, 1H, pyridine), 8.01 (d, J=
7.7 Hz, 2H, Ar), 7.72 (m, 3H, 1×pyridine, 2×Ar), 7.40 (t, J=7.4 Hz,
1H, para-Ar), 4.98 (s, 2H, CH2).
13C NMR (DMSO-d6): δ 149.1 (CH,
pyridine), 148.4 (CH, pyridine), 148.0 (C, Ar), 139.5 (C, pyrazole),
135.4 (CH, pyridine), 129.0 (2×CH, Ar), 128.2 (C, pyrazole), 128.2
(CH, pyridine), 126.9 (2×CH, Ar), 124.1 (CH, para-Ar), 119.2 (CH,
pyrazole), 116.8 (C, pyridine), 37.9 (CH2).
4-(Chloromethyl)-3-(4-ethylphenyl)-1-phenyl-1H-pyrazole (9c)
Prepared from (3-(4-ethylphenyl)-1-phenyl-1H-pyrazol-4-yl)metha-
nol (8c) (0.80 g, 2.87 mmol). The product was eluted with
petroleum ether – EtOAc 9 :1 v/v to give the product as a yellow
solid, yield 0.51 g (82%). M.p. 96–98 °C. TLC (2 :1 petroleum ether/
EtOAc), Rf=0.94. 1H NMR (DMSO-d6): δ 8.74 (s, 1H, pyrazole), 7.89
(d, J=7.7 Hz, 2H, Ar), 7.77 (d, J=7.8 Hz, 2H, Ar), 7.54 (t, J=7.8 Hz,
1H, para-Ar), 7.36 (d, J=8.5 Hz, 4H, Ar), 4.91 (s, 1H, CH2), 2.68 (q, J=
7.4 Hz, 2H, CH2), 1.23 (t, J=7.4 Hz, 3H, CH3).
13C NMR (DMSO-d6):
δ 151.0 (C, pyrazole), 144.5 (C, Ar), 139.6 (C, Ar), 130.7 (C, pyrazole),
130.1 (C, Ar), 130.1 (2×CH, Ar), 128.7 (CH, para-Ar,), 127.8 (2×CH,
Ar), 127.1 (2×CH, Ar), 118.8 (CH, pyrazole), 117.9 (2×CH, Ar), 38.3
(CH2), 28.43 (CH2), 16.0 (CH3). [ESI-HRMS] calculated for C18H18ClN2:
297.6373 [M+H]+. Found: 297.6362 [M+H]+.
4-(Chloromethyl)-1-phenyl-3-(4-propylphenyl)-1H-pyrazole
(9d)
Prepared from (1-phenyl-3-(4-propylphenyl)-1H-pyrazol-4-yl)metha-
nol (8d) (0.70 g, 2.39 mmol). The product was eluted with
petroleum ether – EtOAc 85 :15 v/v to give the product as a brown
solid, yield 0.33 g (82%). M.p. 82–84 °C. TLC (2 :1 petroleum ether/
EtOAc), Rf=0.88. 1H NMR (DMSO-d6): δ 8.09 (s, 1H, pyrazole), 7.77
(m, 4H, Ar), 7.49 (t, J=8.1 Hz, 1H, para-Ar), 7.33 (m, 4H, Ar), 4.76 (s,
2H, CH2), 2.67 (t, J=7.4 Hz, 2H, CH2), 1.72 (sext, J=7.2 Hz, 2H, CH2),
1.00 (t, J=7.3 Hz, 3H, CH3).
13C NMR (DMSO-d6): δ 151.8 (C,
pyrazole), 143.1 (C, Ar), 139.8 (C, Ar), 129.8 (C, Ar), 129.5 (2×CH, Ar),
128.9 (2×CH, Ar), 128.5 (CH, para-Ar), 127.9 (2×CH, Ar), 126.7 (CH,
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pyrazole), 119.1 (2×CH, Ar), 117.7 (C, pyrazole), 37.9 (CH2), 37.3
(CH2), 24.5 (CH2), 13.8 (CH3). [ESI-HRMS] calculated for C19H20ClN2:
311.1312 [M+H]+. Found: 311.1310 [M+H]+.
4-(Chloromethyl)-3-(4-isopropylphenyl)-1-phenyl-1H-pyrazole
(9e)
Prepared from (1-phenyl-3-(4-isopropylphenyl)-1H-pyrazol-4-yl)
methanol (8e) (0.62 g, 2.11 mmol). The product was eluted with
petroleum ether – EtOAc 85 :15 v/v to give the product as a brown
solid, yield 0.53 g (80%). M.p. 114–116 °C. TLC (2 :1 petroleum
ether/EtOAc), Rf=0.85. 1H NMR (DMSO-d6): δ 8.74 (s, 1H, pyrazole),
7.89 (d, J=7.8 Hz, 2H, Ar), 7.78 (d, J=8.1 Hz, 2H, Ar), 7.53 (t, J=
7.7 Hz, 2H, Ar), 7.39 (d, J=8.1 Hz, 2H, Ar), 7.34 (t, J=7.3 Hz, 1H,
para-Ar), 4.90 (s, 2H, CH2), 2.95 (sept, J=6.9 Hz, 1H, CH), 1.25 (d, J=
6.9 Hz, 6H, 2×CH3).
13C NMR (DMSO-d6): δ 151.0 (C, pyrazole), 149.1
(C, Ar), 139.7 (C, Ar), 130.7 (CH, para-Ar), 130.3 (C, Ar), 130.1 (2×CH,
Ar), 127.9 (2×CH, Ar), 127.2 (2×CH, Ar), 127.1 (CH, pyrazole), 118.8
(2×CH, Ar), 117.9 (C, pyrazole), 38.3 (CH2), 33.7 (CH), 24.3 (2×CH3).
[ESI-HRMS] calculated for C19H20ClN2: 311.1312 [M+H]
+. Found:
311.1313 [M+H]+.
4-(Chloromethyl)-3-(4-isobutylphenyl)-1-phenyl-1H-pyrazole
(9 f)
Prepared from (1-phenyl-3-(4-isobutylphenyl)-1H-pyrazol-4-yl)meth-
anol (8f) (2.20 g, 7.17 mmol). The product was obtained as a
greenish brown solid pure enough for use in the next reaction.
Yield 1.90 g (82%). M.p. 100–102 °C. TLC (3 :1 petroleum ether/
EtOAc), Rf=0.62. 1H NMR (DMSO-d6): δ 8.46 (s, 1H, pyrazole), 7.88
(d, J=7.9 Hz, 2H, Ar), 7.79 (d, J=7.7 Hz, 2H, Ar), 7.51 (t, J=7.5 Hz,
2H, Ar), 7.30 (t, J=7.5 Hz, 1H, para-Ar), 7.25 (d, J=7.8 Hz, 2H, Ar),
4.95 (s, 2H, CH2), 2.49 (d, J=7.3 Hz, 2H, CH2), 1.87 (m, 1H, CH), 0.89
(d, J=6.5 Hz, 6H, 2×CH3).
13C NMR (DMSO-d6): δ 149.9 (C, pyrazole),
142.2 (C, Ar), 139.9 (C, Ar), 131.5 (2×CH, Ar), 129.9 (C, Ar), 129.5 (2×
CH, Ar), 126.5 (CH, para-Ar), 124.8 (2×CH, Ar), 123.0 (CH, pyrazole),
120.3 (2×CH, Ar), 119.2 (C, pyrazole), 38.3 (CH2), 36.0 (CH2), 29.0
(CH), 22.7 (2×CH3). [ESI-HRMS] calculated for C20H22ClN2: 325.1472
[M+H]+. Found: 325.1478 [M+H]+.
4-(Chloromethyl)-3-(4-tert-butylphenyl)-1-phenyl-1H-Pyrazole
(9g)
Prepared from (1-phenyl-3-(4-tert-butylphenyl)-1H-pyrazol-4-yl)
methanol (8g) (2.00 g, 6.52 mmol). The product was obtained as a
pale yellow solid pure enough for use in the next reaction. Yield
1.46 g (69%). M.p. 132–134 °C. TLC (1 :1 petroleum ether/EtOAc),
Rf=0.94. 1H NMR (DMSO-d6) δ 8.09 (s, 1H, pyrazole), 7.89 (d. J=
7.6 Hz, 2H, Ar), 7.79 (d, J=8.4 Hz, 2H, Ar), 7.53 (m, 4H, Ar), 7.35 (t,
J=6.5 Hz, 1H, para-Ar), 4.91 (s, 2H, CH2), 1.33 (s, 9H, 3×CH3).
13C
NMR (DMSO-d6): δ 151.3 (C, Ar), 150.9 (C, pyrazole), 139.7 (C, Ar),
130.7 (CH, para-Ar), 130.1 (2×CH, Ar), 129.9 (C, Ar), 127.6 (2×CH,
Ar), 127.0 (CH, pyrazole), 126.0 (2×CH, Ar), 118.8 (2×CH, Ar), 118.0
(C, pyrazole), 38.3 (CH2), 34.9 (C(CH3)3), 31.5 (3×CH3). [ESI-HRMS]
calculated for C20H22ClN2: 325.1466 [M+H]
+. Found: 325.1461 [M+
H]+.
3-(Benzo[d][1,3]
dioxol-5-yl)-4-(chloromethyl)-1-phenyl-1H-pyrazole (9 i)
Prepared from (3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-
yl)methanol (8 i) (0.90 g, 3.068 mmol). The product was eluted with
petroleum ether – EtOAc 85 :15 v/v to give the product as a yellow
solid, yield 0.75 g (76%). M.p. 158–159 °C. TLC (1 :1 petroleum
ether/EtOAc), Rf=0.81. 1H NMR (DMSO-d6): δ 8.54 (s, 1H, pyrazole),
7.81 (d, J=8.0 Hz, 2H, Ar), 7.54 (t, J=7.8 Hz, 2H, Ar), 7.42 (t, J=
7.4 Hz, 1H, Ar), 7.37 (s, 1H, benzo[d][1,3]dioxole), 7.28 (d, J=1.6 Hz,
1H, benzo[d][1,3]dioxole), 6.96 (d, J=8.1 Hz, 1H, benzo[d][1,3]
dioxole), 6.07 (s, 2H, benzo[d][1,3]dioxole), 4.92 (s, 2H, CH2).
13C NMR
(DMSO-d6): δ 151.4 (C, pyrazole), 148.0 (C, Ar), 147.9 (C, benzo[d]
[1,3]dioxole), 139.7 (C, benzo[d][1,3]dioxole), 129.5 (2×CH, Ar),
128.6 (CH, para-Ar), 126.7 (CH, pyrazole), 126.4 (C, benzo[d][1,3]
dioxole), 121.9 (CH, benzo[d][1,3]dioxole), 119.1 (2×CH, Ar), 117.5
(C, pyrazole), 108.6 (CH, benzo[d][1,3]dioxole), 108.5 (CH, benzo[d]
[1,3]dioxole), 101.2 (CH2, benzo[d][1,3]dioxole), 37.2 (CH2). [ESI-
HRMS] calculated for C17H14ClN2O2: 313.0931 [M+H]
+. Found:
313.0919 [M+H]+.
2-Chloro-3-(4-(chlorometh-
yl)-1-phenyl-1H-pyrazol-3-yl)-1H-indole (9 j)
Prepared from (3-(1H-indol-3-yl)-1-phenyl-1H-pyrazol-4-yl)methanol
(8 j) (1.50 g, 5.18 mmol). The product was eluted with petroleum
ether – EtOAc 85 :15 v/v to give the product as a brown waxy solid,
yield 0.90 g (51%). TLC (1 :1 petroleum ether/EtOAc), Rf=0.91. 1H
NMR (CDCl3): δ 11.07 (NH, indole), 8.27 (s, 1H, pyrazole), 7.88 (d, J=
7.6 Hz, 2H, Ar), 7.59 (t, J=7.9 Hz, 2H, Ar), 7.50 (d, J=7.3 Hz, 1H,
indole), 7.43 (t, J=7.5 Hz, 1H, indole), 7.34 (d, J=8.6 Hz, 1H, indole),
7.25 (t, J=7.3 Hz, 1H, indole), 7.16 (t, J=7.5 Hz, 1H, para-Ar), 4.69 (s,
2H, CH2).
13C NMR (CDCl3): δ 145.8 (C, Ar), 139.8 (C, indole), 136.7 (C,
pyrazole), 134.5 (C, indole), 129.8 (2×CH, Ar), 129.5 (CH, para-Ar),
127.5 (CH, indole), 127.4 (C, pyrazole), 127.3 (C, indole), 123.6 (CH,
pyrazole), 120.8 (CH, indole), 120.7 (C, indole), 119.9 (2×CH, Ar),
119.5 (CH, indole), 111.7 (CH, indole), 36.8 (CH2). [ESI-HRMS]
calculated for C18H14Cl2N3: 342.0565 [M+H]
+. Found: 242.0550 [M+
H]+.
3-(Chloromethyl)-1-(4-methoxyphenyl)-5-methyl-1H-pyrazole
(21)
Prepared from 1-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)meth-
anol (19) (2.0 g, 9.16 mmol). The product was eluted with petro-
leum ether – EtOAc 40 :60 v/v to give the product as a brown oil,
yield 1.36 g (63%). TLC (1 :1 hexane/EtOAc), Rf=0.85. 1H NMR
(DMSO-d6): δ δ 7.52 (d, J=9.0 Hz, 2H, Ar), 7.13 (d, J=9.0 Hz, 2H, Ar),
6.44 (s, 1H, pyrazole), 4.87 (s, 2H, CH2), 3.89 (s, 3H, OCH3), 2.29 (s, 3H,
CH3).
13C-NMR (DMSO-d6): δ 159.0 (C, Ar), 148.5 (C, pyrazole), 140.6
(C, pyrazole), 132.7 (C, Ar), 126.6 (2×CH, Ar), 114.7 (2×CH, Ar), 106.7
(CH, pyrazole), 55.9 (OCH3), 39.5 (CH2), 12.4 (CH3). [ESI-HRMS]
calculated for C12H14ClN2O: 237.0795 [M+H]
+. Found: 237.0799 [M
+H]+.
5-(Chloromethyl)-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole
(22)
Prepared from 1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl)meth-
anol (20) (2.0 g, 9.16 mmol). The product was eluted with petro-
leum ether – EtOAc 40 :60 v/v to give the product as a yellow solid,
yield 1.43 g (66%). M.p. 48–50 °C. TLC (1 :1 hexane/EtOAc), Rf=0.71.
1H NMR (DMSO-d6): 7.49 (d, J=9.0 Hz, 2H, Ar), 7.08 (d, J=9.0 Hz, 2H,
Ar), 6.39 (s, 1H, pyrazole), 4.76 (s, 2H, CH2), 3.83 (s, 3H, OCH3), 2.22 (s,
3H, CH3).
13C-NMR (DMSO-d6): δ 159.5 (C, Ar), 148.7 (C, pyrazole),
140.9 (C, pyrazole), 133.0 (C, Ar), 126.8 (2×CH, Ar), 115.0 (2×CH, Ar),
106.9 (CH, pyrazole), 56.2 (OCH3), 39.8 (CH2), 12.7 (CH3). [ESI-HRMS]
calculated for C12H14ClN2O: 237.0795 [M+H]
+. Found: 237.0799 [M
+H]+.
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General Method for the Preparation of Imidazole Derivatives
(10), (23) and (25) and Triazole Derivatives (11), (24) and (26)
To a stirred suspension of K2CO3 (4 mmol) in dry acetonitrile
(10 mL) was added imidazole (4 mmol) or triazole (4 mmol). The
reaction mixture was refluxed at 45 °C for 1 h. After cooling to room
temperature the chloromethyl pyrazole compound (9, 21 or 22)
(1 mmol) was added and the reaction mixture refluxed at 70 °C
overnight. The solvent was evaporated under reduced pressure and
the resulting mixture diluted with EtOAc (50 mL) and washed with
brine (3×20 mL) and H2O (3×20 mL). The organic layer was dried
(MgSO4) and evaporated under reduced pressure to give the crude
imidazole or triazole, which was purified by gradient column
chromatography.
4-(4-((1H-Imidazol-1-yl)methyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (10a)
Prepared from 4-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (9a) (0.20 g, 0.74 mmol). The product was eluted with
CH2Cl2  MeOH  Et3N 91.5 : 7.5 : 1 v/v/v to give the product as a yellow
solid, yield 0.15 g (67%). M.p. 80–82 °C. TLC (9 :1 CH2Cl2/MeOH),
Rf=0.42. 1H NMR (DMSO-d6): δ 8.65 (d, J=5.7 Hz, 2H, pyridine), 8.59
(s, 1H, pyrazole), 7.90 (d, J=7.0 Hz, 2H, Ar), 7.71 (s, 1H, imidazole),
7.66 (d, J=5.3 Hz, 2H, pyridine), 7.55 (t, J=7.4 Hz, 2H, Ar), 7.38 (t,
J=7.2 Hz, 1H, para-Ar), 7.16 (s, 1H, imidazole), 6.89 (s, 1H,
imidazole), 5.40 (s, 2H, CH2).
13C NMR (DMSO-d6): δ 150.6 (2×CH,
pyridine), 147.9 (C, pyridine), 140.1 (C, Ar), 139.5 (C, pyrazole), 135.6
(CH, imidazole), 130.7 (CH, imidazole), 130.1 (2×CH, Ar), 129.2 (CH,
pyrazole), 127.5 (CH, para-Ar), 122.1 (2×CH, pyridine), 119.7 (CH,
imidazole), 119.1 (2×CH, Ar), 118.4 (C, pyrazole), 40.8 (CH2). [ESI-
HRMS] calculated for C18H16N5: 302.1406 [M+H]
+. Found: 302.1392
[M+H]+.
3-(4-((1H-Imidazol-1-yl)methyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (10b)
Prepared from 3-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (9b) (0.50 g, 1.85 mmol). The product was eluted with
CH2Cl2  MeOH  Et3N 89 :10 :1 v/v/v to give the product as a yellow
oil, yield 0.30 g (54%). TLC (9 :1 CH2Cl2/MeOH), Rf=0.46.
1H NMR
(CDCl3): δ 8.86 (s, 1H, pyridine), 8.65 (d, J=4.9 Hz, 1H, pyridine), 7.89
(d, J=7.9 Hz, 1H, pyridine), 7.86 (s, 1H, pyrazole), 7.65 (d, J=7.6 Hz,
2H, Ar), 7.69 (s, 1H, imidazole), 7.56 (s, 1H, imidazole), 7.49 (t, J=
8.4 Hz, 2H, Ar), 7.39 (m, 1H, pyridine), 7.35 (t, J=7.4 Hz, 1H, para-Ar),
7.97 (s, 1H, imidazole), 5.25 (s, 2H, CH2).
13C NMR (CDCl3): δ 149.6
(CH, pyridine), 148.6 (CH, pyridine), 148.2 (C, Ar), 139.4 (C, pyrazole),
135.1 (CH, pyridine), 129.9 (CH, imidazole), 129.6 (2×CH, Ar), 128.5
(C, pyrazole), 128.0 (CH, pyridine), 127.3 (2×CH, Ar), 123.7 (CH, para-
Ar), 123.7 (CH, imidazole), 119.2 (CH, pyrazole), 119.1 (CH,
imidazole), 116.7 (C, pyridine), 41.7 (CH2). [ESI-HRMS] calculated for
C18H16N5: 302.1400 [M+H]
+. Found: 302.1399 [M+H]+.
4-((1H-Imidazol-1-yl)
methyl)-3-(4-ethylphenyl)-1-phenyl-1H-pyrazole (10c)
Prepared from 4-(chloromethyl)-3-(4-ethylphenyl)-1-phenyl-1H-
pyrazole (9c) (0.50 g, 1.68 mmol). The product was eluted with
CH2Cl2  MeOH 95 :5 v/v to give the product as a yellow solid, yield
0.32 g (58%). M.p. 74–76 °C. TLC (9 :1 CH2Cl2/MeOH), Rf=0.83. 1H
NMR (DMSO-d6): δ 7.81 (s, 1H, pyrazole), 7.73 (d, J=9 Hz, 2H, Ar),
7.65 (s, 1H, imidazole), 7.52 (d, J=9 Hz, 2H, Ar), 7.47 (t, J=8.3 Hz,
1H, para-Ar), 7.32 (m, 4H, Ar), 7.12 (s, 1H, imidazole), 6.97 (s, 1H,
imidazole), 5.24 (s, 2H, CH2), 2.72 (q, J=7.6 Hz, 2H, CH2), 1.29 (t, J=
7.5 Hz, 3H, CH3).
13C NMR (DMSO-d6): δ 151.5 (C, pyrazole), 144.8 (C,
Ar), 139.7 (C, Ar), 129.7 (C, pyrazole), 129.7 (CH, imidazole), 129.5 (C,
Ar), 128.4 (2×CH, Ar), 127.8 (CH, para-Ar), 127.6 (2×CH, Ar), 127.4
(2×CH, Ar), 126.7 (CH, imidazole), 119.0 (CH, imidazole), 117.7 (CH,
pyrazole), 116.3 (2×CH, Ar), 41.8 (CH2), 28.7 (CH2), 15.5 (CH3). Anal.
Calcd for C21H20N4 (328.4158): C, 76.80; H, 6.14; N, 17.05. Found: C,
76.68; H, 6.02; N, 17.18.
4-((1H-Imidazol-1-yl)
methyl)-1-phenyl-3-(4-propylphenyl)-1H-pyrazole (10d)
Prepared from 4-(chloromethyl)-3-(4-propylphenyl)-1-phenyl-1H-
pyrazole (9d) (0.50 g, 1.61 mmol). The product was eluted with
CH2Cl2  MeOH 95 :5 v/v to give the product as a brown oil, yield
0.36 g (65%). TLC (9 :1 CH2Cl2/MeOH), Rf=0.87.
1H NMR (CDCl3):
δ 9.03 (s, 1H, pyrazole), 8.37 (s, 1H, imidazole), 7.78 (d, J=8.2 Hz,
2H, Ar), 7.48 (m, 4H, Ar), 7.35 (t, J=7.2 Hz, 1H, para-Ar), 7.30 (d, J=
8.0 Hz, 2H, Ar), 7.28 (s, 1H, imidazole), 6.93 (s, 1H, imidazole), 5.54 (s,
2H, CH2), 2.67 ( t, J=7.7 Hz, 2H, CH2), 1.70 (sext, J=7.4 Hz, 2H, CH2),
0.98 (t, J=7.3 Hz, 3H, CH3).
13C NMR (CDCl3): δ 151.5 (C, pyrazole),
143.2 (C, Ar), 139.7 (C, Ar), 137.0 (CH, imidazole), 129.7 (C, Ar), 129.6
(CH, imidazole), 129.5 (2×CH, Ar), 129.0 (2×CH, Ar), 127.7 (CH,
imidazole), 127.6 (2×CH, Ar), 126.7 (CH, para-Ar), 125.2 (CH,
pyrazole), 117.0 (2×CH, Ar), 116.3 (C, pyrazole), 41.8 (CH2), 37.8
(CH2), 24.5 (CH2), 13.8 (CH3). [ESI-HRMS] calculated for C22H23N4:
343.1917 [M+H]+. Found: 343.1915 [M+H]+.
4-((1H-Imidazol-1-yl)
methyl)-3-(4-isopropylphenyl)-1-phenyl-1H-pyrazole (10e)
Prepared from 4-(chloromethyl)-3-(4-isopropylphenyl)-1-phenyl-1H-
pyrazole (9e) (0.50 g, 1.61 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 : 2.5 v/v to give the product as a brown oil, yield
0.29 g (52%). TLC (9 :1 CH2Cl2/MeOH), Rf=0.74.
1H NMR (DMSO-d6):
δ 8.51 (s, 1H, pyrazole), 7.87 (d, J=8.1 Hz, 2H, Ar), 7.67 (s, 1H,
imidazole), 7.56 (d, J=8.1 Hz, 2H, Ar), 7.53 (t, J=7.6 Hz, 1H, para-
Ar), 7.35 (d, J=8.1 Hz, 4H, Ar), 7.15 (s, 1H, imidazole), 6.90 (s, 1H,
imidazole), 5.30 (s, 2H, CH2), 2.95 (sept, J=6.9 Hz, 1H, CH), 1.25 (d,
J=6.9 Hz, 6H, 2×CH3).
13C NMR (DMSO-d6): δ 150.8 (C, pyrazole),
149.0 (C, Ar), 139.8 (C, Ar), 130.4 (C, Ar), 130.1 (CH, imidazole), 130.0
(2×CH, Ar), 129.1 (CH, imidazole), 127.9 (2×CH, Ar), 127.1 (2×CH,
Ar), 126.9 (CH, para-Ar), 123.1 (CH, pyrazole), 119.7 (CH, imidazole),
118.8 (2×CH, Ar), 117.2 (C, pyrazole), 41.0 (CH2), 33.7 (CH), 24.3 (2×
CH3). [ESI-HRMS] calculated for C22H23N4: 343.1917 [M+H]
+. Found:
343.1917 [M+H]+.
4-((1H-Imidazol-1-yl)
methyl)-3-(4-isobutylphenyl)-1-phenyl-1H-pyrazole (10 f)
Prepared from 3-(4-isobutylphenyl)-4-(chloromethyl)-1-phenyl-1H-
pyrazole (9f) (0.85 g, 2.61 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 : 2.5 v/v to give the product as a yellow oil, yield
0.58 g (62%). TLC (95 :5 CH2Cl2/MeOH), Rf=0.51.
1H NMR (CDCl3):
δ 7.77 (s, 1H, pyrazole), 7.70 (d, J=8.2 Hz, 2H, Ar), 7.54 (s, 1H,
imidazole), 7.48 (d, J=7.8 Hz, 2H, Ar), 7.42 (t, J=7.8 Hz, 2H, Ar), 7.27
(t, J=7.5 Hz, 1H, para-Ar), 7.22 (d, J=8.1 Hz, 2H, Ar), 7.07 (s, 1H,
imidazole), 6.91 (s, 1H, imidazole), 5.16 (s, 2H, CH2), 2.52 (d, J=
7.1 Hz, 2H, CH2), 1.90 (m, 1H, CH), 0.93 (d, J=6.6 Hz, 6H, 2×CH3).
13C
NMR (CDCl3): δ 151.5 (C, pyrazole), 142.3 (C, Ar), 139.6 (C, Ar), 136.9
(CH, imidazole), 129.7 (C, Ar), 129.6 (2×CH, Ar), 129.5 (CH,
imidazole), 129.5 (2×CH, Ar), 127.6 (CH, imidazole), 127.6 (2×CH,
Ar), 126.9 (CH, pyrazole), 126.7 (CH, para-Ar), 118.9 (2×CH, Ar),
116.2 (C, pyrazole), 45.2 (CH2), 41.7 (CH2), 30.2 (CH), 22.4 (2×CH3).
[ESI-HRMS] calculated for C23H25N4: 357.2079 [M+H]
+. Found:
357.2086 [M+H]+.
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4-((1H-Imidazol-1-yl)methyl)-3-(4-(tert-butyl)
phenyl)-1-phenyl-1H-pyrazole (10g)
Prepared from 3-(4-(tert-butyl)phenyl)-4-(chloromethyl)-1-phenyl-
1H-pyrazole (9g) (0.50 g, 1.53 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 :2.5 v/v to give the product as a yellow solid,
yield 0.31 g (57%). M.p. 116–117 °C. TLC (95 :5 CH2Cl2/MeOH), Rf=
0.72. 1H NMR (DMSO-d6): δ 8.52 (s, 1H, pyrazole), 7.87 (d, J=7.8 Hz,
2H, Ar), 7.68 (s, 1H, imidazole), 7.57 (d, J=8.3 Hz, 2H, Ar), 7.53 (t, J=
7.7 Hz, 2H, Ar), 7.49 (d, J=8.3 Hz, 2H, Ar), 7.34 (t, J=7.3 Hz, 1H,
para-Ar), 7.16 (s, 1H, imidazole), 6.91 (s, 1H, imidazole), 5.30 (s, 2H,
CH2), 1.32 (s, 9H, 3×CH3).
13C NMR (DMSO-d6): δ 151.2 (C, Ar), 150.7
(C, pyrazole), 139.8 (C, Ar), 139.8 (C, Ar), 137.5 (CH, imidazole), 130.1
(2×CH, Ar), 130.0 (CH, imidazole), 129.1 (CH, para-Ar), 127.6 (2×CH,
Ar), 126.9 (CH, pyrazole), 126.0 (2×CH, Ar), 119.7 (CH, imidazole),
118.8 (2×CH, Ar), 117.2 (C, pyrazole), 41.0 (CH2), 34.9 (C(CH3)3), 31.5
(3×CH3). Anal. Calcd for C23H24N4 (356.4694): C, 77.50; H, 6.79; N,
15.71. Found: C, 77.92; H, 7.04; N, 15.88.
4-((1H-Imidazol-1-yl)
methyl)-3-([1,1’-biphenyl]-4-yl)-1-phenyl-1H-pyrazole (10h)
Prepared from 3-([1,1’-biphenyl]-4-yl)-4-(chloromethyl)-1-phenyl-1H-
pyrazole (9h)[26] (0.40 g, 1.16 mmol). The product was eluted with
CH2Cl2  MeOH 98 :2 v/v to give the product as a yellow solid, yield
0.20 g (46%). M.p. 114–115 °C. TLC (95 :5 CH2Cl2/MeOH), Rf=0.65.
1H NMR (DMSO-d6): δ 8.56 (s, 1H, pyrazole), 7.90 (d, J=7.6 Hz, 2H,
Ar), 7.77 (m, 6H, Ar), 7.71 (s, 1H, imidazole), 7.54 (t, J=7.9 Hz, 2H,
Ar), 7.50 (t, J=7.8 Hz, 2H, Ar), 7.40 (t, J=7.8 Hz, 1H, para-Ar), 7.36 (t,
J=7.7 Hz, 1H, para-Ar), 7.18 (s, 1H, imidazole), 6.91 (s, 1H,
imidazole), 5.37 (s, 2H, CH2).
13C NMR (DMSO-d6): δ 150.3 (C,
pyrazole), 140.3 (C, Ar), 140.0 (C, Ar), 139.7 (C, Ar), 132.0 (2×CH, Ar),
130.2 (2×CH, Ar), 130.1 (CH, imidazole), 129.5 (2×CH, Ar), 129.1
(CH, imidazole), 128.4 (2×CH, Ar), 128.2 (2×CH, Ar), 127.4 (2×CH,
Ar), 127.1 (2×CH, Ar), 127.0 (CH, para-Ar), 119.7 (CH, imidazole),
118.9 (CH, para-Ar), 117.5 (C, pyrazole), 41.0 (CH2). [ESI-HRMS]
calculated for C25H21N4: 377.1766 [M+H]
+. Found: 377.1770 [M+
H]+.
4-((1H-Imidazol-1-yl)methyl)-3-(benzo[d][1,3]
dioxol-5-yl)-1-phenyl-1H-pyrazole (10 i)
Prepared from 3-(benzo[d][1,3]dioxol-5-yl)-4-(chloromethyl)-1-
phenyl-1H-pyrazole (9 i) (0.60 g, 1.92 mmol). The product was
eluted with CH2Cl2  MeOH 98 :2 v/v to give the product as a yellow
solid, yield 0.32 g (49%). M.p. 62–64 °C. TLC (95 :5 CH2Cl2/MeOH),
Rf=0.47. 1H NMR (CDCl3): δ 7.72 (s, 1H, pyrazole), 7.65 (d, J=7.9 Hz,
2H, Ar), 7.50 (s, 1H, imidazole), 7.39 (t, J=7.6 Hz, 2H, Ar), 7.24 (t, J=
7.4 Hz, 1H, para-Ar), 7.09 (s, 1H, imidazole), 7.06 (s, 1H, benzo[d][1,3]
dioxole), 6.94 (d, J=1.6 Hz, 1H, benzo[d][1,3]dioxole), 6.89 (s, 1H,
imidazole), 6.82 (d, J=8.0 Hz, 1H, benzo[d][1,3]dioxole), 5.93 (s, 2H,
benzo[d][1,3]dioxole), 5.10 (s, 2H, CH2).
13C NMR (CDCl3): δ 151.0 (C,
pyrazole), 148.1 (C, benzo[d][1,3]dioxole), 147.9 (C, benzo[d][1,3]
dioxole), 139.5 (C, Ar), 137.0 (CH, imidazole), 129.7 (CH, imidazole),
129.5 (2×CH, Ar), 127.6 (CH, para-Ar), 126.7 (CH, pyrazole), 121.5
(CH, benzo[d][1,3]dioxole), 118.8 (2×CH, Ar), 118.6 (CH, imidazole),
108.5 (CH, benzo[d][1,3]dioxole), 108.3 (CH, benzo[d][1,3]dioxole),
101.3 (CH2, benzo[d][1,3]dioxole), 41.9 (CH2). [ESI-HRMS] calculated
for C20H17N4O2: 345.1352 [M+H]
+. Found: 345.1366 [M+H]+.
3-(4-((1H-Imidazol-1-yl)
methyl)-1-phenyl-1H-pyrazol-3-yl)-2-chloro-1H-indole (10 j)
Prepared from 2-chloro-3-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-
yl)-1H-indole (9 j) (0.80 g, 2.33 mmol). The product was eluted with
CH2Cl2  MeOH 97 :3 v/v to give the product as a brown oil, yield
0.49 g (56%). TLC (95 :5 CH2Cl2/MeOH), Rf=0.72.
1H NMR (CDCl3):
δ 10.75 (s, 1H, NH), 7.78 (s, 1H, imidazole), 7.63 (d, J=7.7 Hz, 2H,
Ar), 7.48 (d, J=7.4 Hz, 1H, indole), 7.35 (d, J=7.7 Hz, 2H, Ar), 7.32 (s,
1H, pyrazole), 7.19 (d, J=7.5 Hz, 1H, indole), 7.16 (t, J=7.7 Hz, 1H,
para-Ar), 7.05 (m, 2H, indole), 6.94 (s, 1H, imidazole), 6.75 (s, 1H,
imidazole), 4.99 (s, 2H, CH2).
13C NMR (CDCl3): δ 144.6 (C, Ar), 139.8
(C, indole), 134.9 (C, pyrazole), 129.5 (2×CH, Ar), 129.0 (CH,
pyrazole), 127.6 (C, indole), 126.8 (CH, imidazole), 122.9 (C, indole),
120.8 (CH, imidazole), 119.3 (CH, imidazole), 119.1 (2×CH, indole),
119.0 (3×CH, Ar), 118.7 (C, indole), 111.0 (2×CH, indole), 104.4 (C,
pyrazole), 41.9 (CH2). [ESI-HRMS] calculated for C21H17ClN5: 374.1172
[M+H]+. Found: 374.1187 [M+H]+.
4-(4-((1H-1,2,4-Triazol-1-yl)methyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (11a)
Prepared from 4-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (9a) (0.50 g, 1.82 mmol). The product was eluted with
CH2Cl2  MeOH  Et3N 92.5 : 7.5 :1 v/v/v to give the product as a white
solid, yield 0.27 g (48%). M.p. 98–100 °C. TLC (9 :1 CH2Cl2/MeOH),
Rf=0.69. 1H NMR (DMSO-d6): δ 8.67 (m, 3H, 2×pyridine, 1×triazole),
8.60 (s, 1H, pyrazole), 7.98 (s, 1H, triazole), 7.90 (d, J=7.7 Hz, 2H, Ar),
7.78 (d, J=5.8 Hz, 2H, pyridine), 7.55 (t, J=7.7 Hz, 2H, Ar), 7.38 (t,
J=7.2 Hz, 1H, para-Ar), 5.60 (s, 2H, CH2).
13C NMR (CDCl3): δ 152.1
(CH, triazole), 150.6 (2x CH, pyridine), 148.3 (C, Ar), 140.0 (C, Ar),
139.5 (C, Ar), 131.0 (CH, Ar), 130.2 (2x CH, Ar), 127.5 (CH, Ar), 122.3
(2×CH, Ar), 122.1 (CH, triazole), 119.2 (2x CH, Ar), 117.0 (C, Ar), 43.5
(CH2). [ESI-HRMS] calculated for C17H15N6: 303.1358 [M+H]
+. Found:
303.1364 [M+H]+.
3-(4-((1H-1,2,4-Triazol-1-yl)methyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (11b)
Prepared from 3-(4-(chloromethyl)-1-phenyl-1H-pyrazol-3-yl)
pyridine (9b) (0.50 g, 1.82 mmol). The product was eluted with
CH2Cl2  MeOH  Et3N 92.5 : 7.5 : 1 v/v/v to give the product as a yellow
solid, yield 0.31 g (55%). M.p. 110–112 °C. TLC (9 :1 CH2Cl2/MeOH),
Rf=0.68. 1H NMR (DMSO-d6): δ 8.67 (m, 3H, 2×pyridine, 1×triazole),
8.60 (s, 1H, pyrazole), 7.98 (s, 1H, triazole), 7.90 (d, J=7.7 Hz, 2H, Ar),
7.78 (d, J=5.8 Hz, 2H, pyridine), 7.55 (t, J=7.7 Hz, 2H, Ar), 7.38 (t,
J=7.2 Hz, 1H, para-Ar), 5.60 (s, 2H, CH2).
13C NMR (CDCl3): δ 152.1
(CH, triazole), 150.6 (2x CH, pyridine), 148.3 (C, Ar), 140.0 (C, Ar),
139.5 (C, Ar), 131.0 (CH, Ar), 130.2 (2x CH, Ar), 127.5 (CH, Ar), 122.3
(2×CH, Ar), 122.1 (CH, triazole), 119.2 (2x CH, Ar), 117.0 (C, Ar), 43.5
(CH2). [ESI-HRMS] calculated for C17H15N6: 303.1358 [M+H]
+. Found:
303.1364 [M+H]+. 1H NMR (CDCl3): δ 8.96 (s, 1H, pyrazole), 8.68 (s,
1H, triazole), 8.08 (s, 1H, pyridine), 8.05 (s, 1H, triazole), 8.02 (m, 2H,
pyridine), 7.75 (d, J=7.6 Hz, 2H, Ar), 7.51 (t, J=7.4 Hz, 2H, Ar), 7.43
(t, J=6.2 Hz, 1H, pyridine), 7.37 (t, J=7.4 Hz, 1H, para-Ar), 5.48 (s,
2H, CH2).
13C NMR (CDCl3): δ 152.5 (CH, triazole), 149.4 (CH, pyridine),
148.5 (CH, pyridine), 148.4 (C, Ar), 139.4 (C, pyrazole), 135.5 (CH,
pyridine), 129.6 (2×CH, Ar), 128.8 (CH, triazole), 128.5 (C, pyrazole),
127.3 (CH, para-Ar), 123.8 (CH, pyridine), 119.2 (2×CH, Ar), 119.1
(CH, pyrazole), 115.0 (C, pyridine), 44.2 (CH2). [ESI-HRMS] calculated
for C17H15N6: 303.1353 [M+H]
+. Found: 303.1352 [M+H]+.
3-((1H-Imidazol-1-yl)
methyl)-1-(4-methoxyphenyl)-5-methyl-1H-pyrazole (23)
Prepared from 3-(chloromethyl)-1-(4-methoxyphenyl)-5-methyl-1H-
pyrazole (21) (1 g, 4.22 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 : 2.5 v/v to give the product as a brown oil, yield
0.65 g (58%). TLC (9 :1 CH2Cl2/MeOH), Rf=0.47.
1H NMR (CDCl3):
δ 7.43 (s, 1H, imidazole), 7.16 (d, J=8.9 Hz, 2H, Ar), 7.08 (s, 1H,
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imidazole), 6.96 (d, J=8.8 Hz, 2H, Ar), 6.82 (s, 1H, imidazole), 6.18 (s,
1H, pyrazole), 5.08 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 2.34 (s, 3H, CH3).
13C NMR (CDCl3): δ 159.3 (C, Ar), 147.6 (C, pyrazole), 140.7 (C,
pyrazole), 137.2 (CH, imidazole), 132.4 (C, Ar), 129.4 (CH, imidazole),
126.5 (2×CH, Ar), 119.3 (CH, imidazole), 114.6 (2×CH, Ar), 105.7
(CH, pyrazole), 55.6 (OCH3), 44.8 (CH2), 12.2 (CH3). [ESI-HRMS]
calculated for C15H17N4O: 269.1397 [M+H]
+. Found: 269.1395 [M+
H]+.
5-((1H-Imidazol-1-yl)
methyl)-1-(4-methoxyphenyl)-3-methyl-1H-pyrazole (25)
Prepared from 5-(chloromethyl)-1-(4-methoxyphenyl)-3-methyl-1H-
pyrazole (22) (1 g, 4.22 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 : 2.5 v/v to give the product as a brown oil, yield
0.71 g (63%). TLC (9 :1 CH2Cl2/MeOH), Rf=0.42.
1H NMR (CDCl3):
δ 7.94 (s, 1H, imidazole), 7.34 (d, J=8.9 Hz, 2H, Ar), 7.19 (s, 1H,
imidazole), 7.12 (s, 1H, imidazole), 7.01 (d, J=8.9, 2H, Ar), 6.08 (s,
1H, pyrazole), 5.20 (s, 2H, CH2), 3.88 (s, 3H, OCH3), 2.27 (s, 3H, CH3).
13C NMR (CDCl3): δ 159.6 (C, Ar), 147.8 (C, pyrazole), 140.9 (C,
pyrazole), 137.5 (CH, imidazole), 132.6 (C, Ar), 129.7 (CH, imidazole),
126.8 (2×CH, Ar), 119.6 (CH, imidazole), 114.7 (2×CH, Ar), 106.0
(CH, pyrazole), 55.8 (OCH3), 45.0 (CH2), 12.5 (CH3). [ESI-HRMS]
calculated for C15H17N4O: 269.1397 [M+H]
+. Found: 269.1396 [M+
H]+.
1-((1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)
methyl)-1H-1,2,4-triazole (24)
Prepared from 3-(chloromethyl)-1-(4-methoxyphenyl)-5-methyl-1H-
pyrazole (21) (0.5 g, 2.11 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 : 2.5 v/v to give the product as a brown oil, yield
0.49 g (86%). TLC (9 :1 CH2Cl2/MeOH), Rf=0.45.
1H NMR (CDCl3):
δ 7.95 (s, 1H, triazole), 7.84 (s, 1H, triazole), 7.24 (m, 2H, Ar), 6.97 (m,
2H, Ar), 6.24 (s, 1H, pyrazole), 5.31 (s, 2H, CH2), 3.86 (s, 3H, OCH3),
2.33 (s, 3H, CH3).
13C NMR (CDCl3): δ 159.4 (C, Ar), 151.8 (CH, triazole),
146.0 (C, pyrazole), 140.7 (C, pyrazole), 132.5 (C, Ar), 126.7 (CH,
triazole), 126.4 (2×CH, Ar), 114.3 (2×CH, Ar), 105.8 (CH, para-Ar),
55.6 (OCH3), 47.4 (CH2), 12.3 (CH3). [ESI-HRMS] calculated for
C14H16N5O: 270.1349 [M+H]
+. Found: 270.1347 [M+H]+.
1-((1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5-yl)
methyl)-1H-1,2,4-triazole (26)
Prepared from 5-(chloromethyl)-1-(4-methoxyphenyl)-3-methyl-1H-
pyrazole (22) (1.0 g, 4.22 mmol). The product was eluted with
CH2Cl2  MeOH 97.5 : 2.5 v/v to give the product as a brown
crystalline solid, yield 1.02 g (90%). M.p. 47–48 °C. TLC (97.5 : 2.5
CH2Cl2/MeOH), Rf=0.43.
1H NMR (DMSO-d6): δ 8.20 (s, 1H, triazole),
7.98 (s, 1H, triazole), 7.33 (d, J=8.4 Hz, 2H, Ar), 6.99 (d, J=8.5 Hz,
2H, Ar), 6.16 (s, 1H, pyrazole), 5.48 (s, 2H, CH2), 3.86 (s, 3H, OCH3),
2.26 (s, 3H, CH3).
13C NMR (CDCl3): δ 159.6 (C, Ar), 152.0 (CH, triazole),
146.2 (C, pyrazole), 140.9 (C, pyrazole), 132.7 (C, Ar), 126.9 (CH,
triazole), 126.7 (2×CH, Ar), 114.4 (2×CH, Ar), 106.0 (CH, para-Ar),
55.7 (OCH3), 47.6 (CH2), 12.6 (CH3). Anal. Calcd for C14H15N5O
(269.3054): C, 62.44; H, 5.61; N, 25.99. Found: C, 62.32; H, 5.39; N,
26.07.
General Method for the Preparation of N-(3-(1H-Imidazol-1-yl)
propyl)-1-phenyl-3-(pyridin-3/4-yl)-1H-pyrazole-4-carboxami-
des (13) and
1-phenyl-3-(pyridin-3/4-yl)-N-(pyridin-4-ylmeth-
yl)-1H-pyrazole-4-carboxamides (14)
To a stirred solution of 1-phenyl-3-(pyridin-3/4-yl)-1H-pyrazole-4-
carboxylic acid (12)[14] (1.5 mmol) in dry DMF (15 mL), was added
CDI (2.2 mmol) at room temperature with continuous stirring for
2 h. The reaction was chilled in an ice-cooled water bath and for
the preparation of 13 1-(3-aminopropyl)imidazole (1.55 mmol) was
added, or for the preparation of 14 4-(aminomethyl)pyridine
(1.7 mmol) was added. The mixture was refluxed at 70 °C for 48 h,
then DMF was evaporated under vacuum, and the residue was
extracted with EtOAc (100 mL). The organic layer was washed with
water (3×50 mL), dried (MgSO4) and evaporated under vacuum.
The product was purified by gradient column chromatography and
eluted with 5% MeOH in CH2Cl2.
N-(3-(1H-Imidazol-1-yl)
propyl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazole-4-carboxamide
(13a)
Prepared from 1-phenyl-3-(pyridin-4-yl)-1H-pyrazole-4-carboxylic
acid (12a)[14] (0.43 g, 1.62 mmol) and 1-(3-aminopropyl)imidazole
(0.2 mL, 1.67 mmol). The product was obtained as a white solid,
yield 0.2 g (33%). M.p. 104–106 °C. TLC (9 :1 CH2Cl2/MeOH), Rf=
0.29. 1H NMR (DMSO-d6): δ 9.01 (s, 1H, pyrazole), 8.64 (d, J=6.0 Hz,
2H, pyridine), 8.46 (t, J=5.4 Hz, 1H, NH), 7.93 (d, J=8.4 Hz, 2H, Ar),
7.87 (d, J=6.1 Hz, 2H, pyridine), 7.83 (s, 1H, imidazole), 7.77 (s, 1H,
imidazole), 7.59 (t, J=7.6 Hz, 2H, Ar), 7.43 (t, J=7.4 Hz, 1H, para-Ar),
7.26 (s, 1H, imidazole), 4.07 (t, J=6.8 Hz, 2H, CH2), 3.08 (q, J=7.3 Hz,
2H, CH2), 1.98 (quint, J=6.8 Hz, 2H, CH2).
13C NMR (CDCl3): δ 163.0
(C=O), 150.2 (2×CH, pyridine), 148.6 (C, pyridine), 140.0 (C, Ar),
139.1 (C, pyrazole), 130.2 (CH, imidazole), 130.2 (CH, para-Ar), 129.7
(4×CH, Ar), 127.8 (CH, pyrazole), 123.2 (2×CH, imidazole), 119.4 (2×
CH, pyridine), 118.2 (C, pyrazole), 45.0 (CH2), 37.3 (CH2), 31.0 (CH2).
[ESI-HRMS] calculated for C21H21N6O: 373.1777 [M+H]
+. Found:
373.1789 [M+H]+.
N-(3-(1H-Imidazol-1-yl)
propyl)-1-phenyl-3-(pyridin-3-yl)-1H-pyrazole-4-carboxamide
(13b)
Prepared from 1-phenyl-3-(pyridin-3-yl)-1H-pyrazole-4-carboxylic
acid (12b)[14] (0.43 g, 1.62 mmol) and 1-(3-aminopropyl)imidazole
(0.2 mL, 1.67 mmol). The product was obtained as a white solid,
yield 0.15 g (25%). M.p. 80–82 °C. TLC (9 :1 CH2Cl2/MeOH), Rf=0.27.
1H NMR (DMSO-d6): δ 9.00 (s, 1H, pyridine), 8.98 (s, 1H, pyrazole),
8.59 (d, J=3.7 Hz, 1H, pyridine), 8.33 (t, J=5.5 Hz, 1H, NH), 8.23 (d,
J=7.8 Hz, 1H, pyridine), 7.92 (d, J=7.8 Hz, 2H, Ar), 7.66 (s, 1H,
imidazole), 7.59 (t, J=7.6 Hz, 2H, Ar), 7.47 (m, 1H, pyridine), 7.42 (t,
J=7.3 Hz, 1H, para-Ar), 7.21 (s, 1H, imidazole), 6.90 (s, 1H,
imidazole), 4.05 (t, J=6.8 Hz, 2H, CH2), 3.21 (q, J=6.2 Hz, 2H, CH2),
1.95 (quint, J=6.8 Hz, 2H, CH2).
13C NMR (DMSO-d6): δ 163.0 (C=O),
150.0 (2×CH, pyridine), 149.6 (CH, pyridine), 149.6 (CH, pyridine),
149.3 (C, pyrazole), 148.8 (C, pyridine), 139.4 (C, Ar), 136.4 (CH,
pyridine), 131.0 (CH, pyridine), 130.3 (2×CH, Ar), 128.8 (C, pyridine),
127.8 (2×CH, pyridine), 123.6 (CH, pyrazole), 122.7 (2×CH, Ar),
120.2 (C, pyrazole), 119.3 (CH, para-Ar), 41.9 (CH2). Anal. Calcd for
C21H20N6O (372.4286): C, 67.08; H, 5.47; N, 22.35. Found: C, 66.93; H,
5.57; N, 22.44.
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1-Phenyl-3-(pyridin-4-yl)-N-(pyridin-4-ylmeth-
yl)-1H-pyrazole-4-carboxamide (14a)
Prepared from 1-phenyl-3-(pyridin-4-yl)-1H-pyrazole-4-carboxylic
acid (12a) (0.46 g, 1.73 mmol) and 4-(aminomethyl)pyridine
(0.2 mL, 1.97 mmol). The product was obtained as a white solid,
yield 0.25 g (41%). M.p. 206–208 °C. TLC (95 :5 CH2Cl2/MeOH), Rf=
0.25. 1H NMR (DMSO-d6): δ 9.09 (s, 1H, pyrazole), 8.97 (t, J=5.8 Hz,
1H, NH), 8.63 (d, J=6 Hz, 2H, pyridine), 8.54 (d, J=5.9 Hz, 2H,
pyridine), 7.94 (d, J=7.8 Hz, 2H, Ar), 7.86 (d, J=6.0 Hz, 2H, pyridine),
7.60 (t, J=7.8 Hz, 2H, Ar), 7.43 (t, J=7.4 Hz, 1H, para-Ar), 7.37 (d, J=
5.8 Hz, 2H, pyridine), 4.50 (d, J=5.9 Hz, 2H, CH2).
13C NMR (DMSO-
d6): δ 163.0 (C=O), 150.1 (4×CH, pyridine), 149.0 (C, pyrazole), 148.7
(C, pyridine), 140.0 (C, pyridine), 139.3 (C, Ar), 131.4 (CH, pyrazole),
130.3 (2×CH, Ar), 128.0 (CH, para-Ar), 123.1 (2×CH, pyridine), 122.7
(2×CH, pyridine), 119.4 (2×CH, Ar), 118.4 (C, pyrazole), 42.0 (CH2).
[ESI-HRMS] calculated for C21H18N5O: 356.1511 [M+H]
+. Found:
356.1523 [M+H]+.
1-Phenyl-3-(pyridin-3-yl)-N-(pyridin-4-ylmeth-
yl)-1H-pyrazole-4-carboxamide (14b)
Prepared from 1-phenyl-3-(pyridin-3-yl)-1H-pyrazole-4-carboxylic
acid (12a) (0.51 g, 1.91 mmol) and 4-(aminomethyl)pyridine
(0.22 mL, 2.17 mmol). The product was obtained as a white solid,
yield 0.32 g (48%). M.p. 206–208 °C. TLC (9 :1 CH2Cl2/MeOH), Rf=
0.88. 1H NMR (DMSO-d6): δ 9.10 (s, 1H, pyridine), 9.00 (s, 1H, NH),
8.91 (t, J=5.6 Hz, 1H, pyridine), 8.58 (d, J=3.8 Hz, 1H, pyridine),
8.53 (d, J=4.9 Hz, 2H, pyridine), 8.21 (d, J=7.8 Hz, 1H, pyridine),
7.92 (d, J=7.8 Hz, 2H, Ar), 7.59 (t, J=7.7 Hz, 2H, Ar), 7.45 (m, 2H,
pyridine), 7.36 (t, J=7.5 Hz, 1H, para-Ar), 4.49 (d, J=5.8 Hz, 2H,
CH2).
13C NMR (DMSO-d6): δ 163.0 (C=O), 150.0 (2×CH, pyridine),
149.6 (CH, pyridine), 149.6 (CH, pyridine), 149.3 (C, pyrazole), 148.8
(C, pyridine), 139.4 (C, Ar), 136.4 (CH, pyridine), 131.0 (CH, pyridine),
130.3 (2×CH, Ar), 128.8 (C, pyridine), 127.8 (2×CH, pyridine), 123.6
(CH, pyrazole), 122.7 (2×CH, Ar), 120.2 (C, pyrazole), 119.3 (CH,
para-Ar), 41.9 (CH2). Anal. Calcd for C21H17N5O (355.3982): C, 70.97;
H, 4.82; N, 19.70. Found: C, 71.05; H, 4.79; N, 19.55.
Biochemistry
CYP121A1 Spectral binding assays for ligand KD determination:
CYP121A1 protein was expressed and purified as described
previously.[20] Ligand binding assays were performed by spectro-
photometric titration using a Cary 60 UV-visible scanning spectro-
photometer (Agilent, UK) and a 1 cm path length quartz cuvette,
recording spectra between 250 and 800 nm. Titrations were
typically done with 3–5 μM CYP121A1 at 25 °C in 100 mM
potassium phosphate (KPi) buffer, 200 mM KCl, pH 7.85 with
0.004% Triton X-100. Ligand stock solutions were prepared in
dimethylsulfoxide (DMSO). Ligands were added in small volumes
(typically 0.05–0.2 μL aliquots) from concentrated stock solutions to
the protein in a 1 mL final volume. Spectral measurements were
taken before ligand addition, and following addition of each aliquot
of ligand until no further spectral change occurred. Difference
spectra at each stage in the titration were obtained by subtraction
of the initial ligand-free enzyme spectrum from subsequent spectra
collected after each addition of ligand. From the difference spectra,
a pair of wavelengths were identified and defined as the
absorbance maximum (Apeak) and minimum (Atrough). The overall
absorbance change (ΔAmax) was calculated by subtracting the Atrough
value from the Apeak value for each spectrum collected after a ligand
addition. Graphs of ΔAmax against [ligand] were plotted for each
titration. Titrations were done in triplicate and the final KD value
presented was determined as the average value across the three
sets. The KD values were determined by fitting the data using either
a standard hyberbolic function (Equation 1) or the Hill equation
(Equation 2) using Origin software (OriginLab, Northampton, MA).
Aobs ¼ ðAmax*L=ðKd þ LÞÞ (1)
In Equation 1 (the standard hyperbolic function, the Michaelis-
Menten function adapted for ligand binding), Aobs is the observed
absorbance change at ligand concentration L, Amax is the maximal
absorbance change observed at apparent ligand saturation, and Kd
is the dissociation constant for the binding of the ligand (the
substrate concentration at which Aobs=0.5×Amax).
Aobs ¼ ðAmax � LnÞ=ðKn þ LnÞ (2)
In Equation 2 (the sigmoidal Hill equation), Aobs is the observed
absorbance change at ligand concentration L, Amax is the absorb-
ance change at apparent ligand saturation, K is the apparent
dissociation constant, and n is the Hill coefficient, a value describing
the apparent extent of cooperativity observed in ligand binding.
Antimycobacterial Activity Assay: M. tuberculosis H37Rv was grown
in 7H9 liquid medium with 10% Middlebrook OADC Growth
Supplement enrichment (BBL/Becton-Dickinson, Sparks, MD, USA).
Cells were cultured at 37 °C until mid-log phase was reached
(OD600nm=0.4–0.6). After cells reached mid-log phase, bacterial
suspensions were prepared as described below and REMA assays
were performed. The anti-M. tuberculosis activities of the com-
pounds were determined by the REMA (Resazurin Microtiter Assay)
method.[21] Stock solutions of the tested compounds (10 mg/mL)
were prepared in DMSO and diluted in Middlebrook 7H9 broth
supplemented with 10% OADC. The microdilution of the com-
pounds was performed in 96-well plates to obtain final compound
concentration ranges of 0.39–100 μg/mL. Rifampicin in the concen-
tration range between 0.004–1 μg/mL was added as control.
Bacterial suspensions were prepared and their turbidity adjusted to
match the optical density of McFarland no. 1 standard. After a
further dilution of 1 :20 in Middlebrook 7H9 broth supplemented
with OADC, 100 μL of the inoculum were added to each well of the
96-well plate. Cultures were incubated for 7 days at 37 °C, and
30 μL of 0.01% resazurin was added. Wells were read after 24 h for
colour change and measured as the fluorescence (excitation/
emission of 530/590 nm filters, respectively) in a microfluorimeter.
The MIC was defined as the lowest concentration resulting in 90%
inhibition of M. tuberculosis growth. The presented results are
representative from two independent experiments.
Molecular Modeling and Docking
Docking studies were performed using the MOE[22] program and
Mtb CYP121A1 co-crystallized with fluconazole (PDB 2IJ7). All
minimisations were performed with MOE until a RMSD gradient of
0.01 Kcal/mol/A with the MMFF94 forcefield and partial charges
were automatically calculated. The charge of the heme iron at
physiological pH was set to 3+ (geometry d2sp3) through the atom
manager in MOE. The Alpha Triangle placement, which derives
poses by random superposition of ligand atom triplets through
alpha sphere dummies in the receptor site, was chosen to
determine the poses. The London ΔG scoring function estimates
the free energy of binding of the ligand from a given pose.
Refinement of the results was done using the MMFF94 forcefield,
and rescoring of the refined results using the London ΔG scoring
function was applied. The output database dock file was created
with different poses for each ligand and arranged according to the
final score function (S), which is the score of the last stage that was
not set to zero.
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Crystallography Studies on CYP121A1
Untagged CYP121A1 protein and crystals were prepared as
previously reported, with the following adaptations.[20] Crystals
were prepared using a Mosquito pipetting robot (Molecular
Dimensions, Newmarket, UK) in 800 nL drops with protein-to-
mother liquor at a ratio of 1 : 1, by vapour diffusion in 1.5–2.1 M
ammonium sulfate and 0.1 M sodium MES, or Cacodylate from
pH 5.5–6.15. Co-crystals were prepared following incubation with
2 mM ligand prepared in DMSO. Protein solutions were centrifuged
at 14,000 rpm for 20 mins at 4 °C immediately before crystallo-
genesis. Ligand soaks were also carried out either by directly
dissolving solid ligand to saturation, or by the addition of a 2–5 mM
ligand solution in DMSO to the mother liquor, and soaking was
carried out for a minimum period of 24 h. Crystals were immersed
in mother liquor supplemented with 10–30% oil as cryoprotectant,
and cryoprotected and flash-cooled in liquid nitrogen. Data were
collected on beamline i02 (wavelength 0.9795 Å) at the Diamond
Light Source Facility (Harwell, UK). The diffraction data were
reduced, scaled and merged using XDS or Xia2.[27,28] Structures were
refined using PHENIX[29] with the native CYP121A1 structure (PDB
1 N40)[20] as the starting model. Structural rebuilding and validation
were performed with COOT,[30] Molprobity[31] and PDB REDO.[32]
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